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Stochastic models are developed to capture the inherent stochasticity of the biochemical 
networks associated to many biological processes. The objective of the present thesis is to 
present a detailed picture of stochastic approach for the mathematical modeling of eukaryotic 
cell cycle, to demonstrate an important application of such model in chemotherapy and to present 
a methodology for selecting the model parameters. The stochastic cell cycle model, developed 
using stochastic chemical kinetics approach, leads to the formation of an infinite dimensional 
differential equation in probabilities of system being in a specific state. Using Monte Carlo 
simulations of this model, dynamics of populations of eukaryotic cells such as yeasts or 
mammalian cells are obtained. Simulations are stochastic in nature and therefore exhibit 
variability among cells that is similar to the variability observed in natural populations. The 
model‟s capability to predict heterogeneities in cell populations is used as a basis to implement it 
in a chemotherapic modeling framework to demonstrate how the model can be used to assist in 
the drug development stage by investigating drug administration strategies that can have 
different killing effect on cancer cells and healthy cells.  
Finally, basic cell cycle model is refined in a systematic way to make it more suitable for 
describing the population characteristics of budding yeast. Selection of model parameters using 
an evolutionary optimization strategy referred to as insilico evolution is described. The benefits 
of this approach lie in the fact that it generates an initial guess of reasonable set of parameters 
which in turn can be used in the least squares fitting of model to the steady state distributions 
obtained from flow cytometry measurements. The Insilco evolution algorithm serves as a tool for 
sensitivity analysis of the model parameters and leads to a synergistic approach of model and 




To conclude, the stochastic model based on single cell kinetics will be useful for 
predicting the population distribution on whole organism level. Such models find applications in 
wide areas of biological and biomedical applications. Evolutionary optimization strategies can be 





CHAPTER 1. INTRODUCTION 
1.1 Eukaryotic Cell Cycle - Overview  
Cell cycle is an orderly sequence of events by which cells replicate and divide into two 
daughter cells with identical genetic material. The eukaryotic cell cycle is divided into four 
different phases: gap phase -G1, synthesis (S) phase, gap phase -G2 and mitosis (M) phase. DNA 
is replicated once per cell cycle in the S phase, duplicated chromosomes are separated and 
moved to two opposite poles of mitotic spindle in the M phase. S and M phases are separated in 
time by the gaps G1, G2. G1 precedes S phase and prepares cell for DNA replication; G2 
precedes M phase and prepares cell for division.  M phase is separated into five sub phases: 
prophase - the extended duplicated genome condenses into chromosomes, which are highly 
ordered structures and metabolic activity is reduced; prometaphase - the nuclear envelope breaks 
and microtubules elongate from centromeres; metaphase - condensed chromosomes align 
properly in the metaphase plane; anaphase - the duplicated chromosomes are separated into two 
identical parts and move towards the opposite poles of the spindle; telophase - the chromosomes 
decondensate, metabolic activity is restored, and the nuclear envelope is reconstructed. The cell 
cycle ends with cytokinesis where the cell divides into two each with same copies of genetic 
material. The duration of the total cell cycle varies for different species and for different tissues 
in the same species.  
Cell cycle has surveillance mechanisms that control the progress of cell through the four 
phases and ensure the crucial processes of replication and division are performed with high 
fidelity. These are called checkpoint controls which include both internal and external control 
mechanisms. The internal mechanisms monitor the timely completion of critical cell cycle events 




three important events – DNA damage, replication blocks and mitotic spindle damage. Main 
sources of DNA damage are environmental agents - genotoxic chemicals, UV and ionizing 
radiation; highly reactive free radicals, by products of cellular metabolism; cell physiological 
conditions that disintegrate the chemical bonds in DNA. These damages occur as single strand 
breaks (SSBs), double strand breaks (DSBs), point mutations. Replication blocks occur during 
DNA synthesis due to insufficient nucleotides and proteins or lesions on the DNA templates 
halting synthesis of DNA strands. Inactivation or under-expression of the proteins involved in 
the spindle formation causing misalignment of chromosomes resulting in mitotic spindle defects. 
 Checkpoints not only detect DNA damage and replication blocks, but also form an 
integral part of multifaceted network of repair pathways that arrest the cell cycle progression to 
allow sufficient time for repair, initiate the transcription of proteins involved in repair and 
apoptosis or programmed cell death. Apoptosis occurs in multi-cellular organisms like mammals 
to prevent the defective cell from harming the whole organism when the damage is too severe to 
repair. A variety of proteins play crucial roles in DNA damage response pathways at various 
stages by sensing the defects in cell cycle, transferring these signals to activate or transcribe 
effector-proteins which carry out the corrective actions. Also, if there are spindle defects, cell is 
arrested in the metaphase to allow time for related proteins to align the chromosomes properly. 
Although there are differences in the number of molecules involved in the cell cycle 
control system (CCCS) that regulates the eukaryotic cell cycle of different species,  it is well-
preserved through the evolutionary history and all eukaryotes share similar set of key compounds 
and interactions. The core of CCCS is a special group of enzymes called cyclin-dependent 
kinases (Cdks). Cdks are maintained at constant level throughout the cell cycle and are in their 




phases of cell cycle progression and their Cdk/cyclin complexes control the transition between 
the phases. Cyclin levels are maintained by controlled proteolysis and transcription, two 
regulatory processes that are important for cell cycle progression. If DNA damage is detected, or 
if the cell growth is not sufficient to have synthesized required amounts of cyclins, the cell cycle 
will be arrested in G1 phase. Cell enters into M-phase from G2 only if the DNA replication is 
complete and the duplicated chromosomes are properly attached to opposite poles of mitotic 
spindle. The transition from metaphase to anaphase which drives the separation of chromosomal 
spindle and exit of mitosis, occurs when M-phase Cdk/cyclin complexes phosphorylate anaphase 
promoting complex (APC) that in turn causes the proteolytic degradation of cyclins and of 
proteins that hold the sister chromatids (duplicated chromosomes) together. Cdks and APC are 
antagonistic in nature - the activated Cdk/cyclin activates conversion of APC to its inactive form 
while active APC inactivates the Cdks by promoting the degradation of cyclins and the activation 
of Cdk-inhibitors (CKIs). 
1.2 Significance of Studying the Cell Cycle 
Excellent reviews on the cell cycle regulation and its significance are presented in the 
literature (Nurse, 2000; Tyers, 2004; Morgan, 2006). All the living organisms should maintain a 
balance between the growth and division of cells for having control over cell size, for surviving 
under different nutrient conditions and environment, and for performing all other key biological 
processes. The imbalance between the growth and division is the key feature of tumors. Cell 
cycles have great influence on neuronal, cardiovascular activities. Thus, many biological 
functions are cell cycle dependent and understanding and controlling the cell cycle is highly 




normal cells causing diseases like Alzheimer's. Inactivation of genes involved in apoptosis is 
another cause of growing tumors. 
Occurrence of many diseases is related to the defects in the cell cycle regulatory system. 
Any defects to the genes involved in the cell cycle checkpoint pathways, repair mechanisms 
result in chromosomal instability, mutations to crucial genes in the cell cycle growth regulation 
and physiology leading to cancer, immunodeficiency and many disorders (Hanahan and  
Weinberg, 2000). Cancer is caused by the genetic imbalance between the proliferation and 
suppression mechanisms of normal cells resulting in their uncontrolled growth. Various types of 
DNA damage discussed earlier, when unrepaired, will cause mutations to genes involved in the 
mechanisms that control proliferation and cell death which will be carried to many generations. 
These permanent mutations cause the activation of oncogenes that stimulate the proliferation or 
protection against cell death and the inactivation of tumor suppressor genes which would 
normally inhibit proliferation. This uncontrolled growth of cells leads to tumors in many cancer 
cells. 
Detailed study of cell cycle physiology helps in better understanding the biological 
processes. Developmental biology is the study of the processes that give rise to tissues, organs 
and organisms in specific shapes and patterns. These processes are controlled by biochemical 
reactions which are closely related to the cell cycle. Cell migration which is a phenomenon 
important in wound healing, tumor growth or apoptosis is influenced by two factors, cell cycle 
phase and the cell size (Fuss et al., 2005).
 
1.3 Mathematical Modeling as a Tool for the Study of Cell Cycle 
 Earlier research in cellular processes involved identifying the important components of 




cycle components occur at different spatial and temporal scales. With the advances in 
experimental technology, experimental observations are possible to obtain at these different 
scales. However, to better understand how these molecular interactions act in a system to 
regulate the biological functions responsible for disease progression, development and other 
cellular activities, a systems level analysis is required. Mathematical modeling provides a better 
analysis tool for gaining system level understanding of the interactions of many components 
acting in diverse ways.  
Mathematical modeling can be used as a valuable tool in hypothesis testing. Hypotheses 
are made about the mechanisms and functions of the cell cycle control system and a 
mathematical model formed based on this hypothesis with proper assumptions will generate 
predictions. The predictions from the model also will be helpful in estimating the key kinetic 
parameters which are sometime difficult to measure. Based on the agreement of the model 
predictions with the experimental observations, the hypothesis can be accepted, rejected or 
modified to form a new hypothesis which gives directions to the design of new experiments. In 
this way, mathematical modeling in synergism with the experiments will be useful as a tool for 
identifying more realistic representations of the cell cycle molecular network and to achieve 
better predictions of the biological phenomena. 
 Another application of mathematical modeling is to predict the behavior of cells subject 
to different environmental conditions. The behavior of cells is generally measured in terms of the 
concentrations of the cell cycle components or the growth of a cell population. One major 
application is in the cancer chemotherapy, where mathematical model is used to predict the 
response of cells to chemotherapic drugs. The predictive capabilities of mathematical models 




1.4 Mathematical Models – Deterministic and Stochastic Approaches 
Mathematical modeling involves converting the interactions among the proteins, enzymes 
in the biochemical network to mathematical relationships which are mainly rates of synthesis and 
degradation of proteins, association or dissociation reactions between two proteins. It is 
important to know the mathematical form of these relationships. Mass action kinetics, Michaelis-
Menten kinetics or simple switch-like functions such as Goldbeter-Koshland function are some 
of the forms used in variety of models. Two main approaches for modeling cellular networks are 
deterministic and stochastic. The deterministic approach assumes average concentrations of the 
cell cycle proteins and such approach will always give the same time trajectory of molecular 
concentrations for specific parameters and initial system state expressed in terms of molecular 
concentrations. The relationships among the reacting components are converted to differential 
equations. Once the kinetic rate parameters are assigned and the initial conditions are specified, 
the differential equations can be solved using numerical integration techniques to obtain the 
concentration of various proteins with time. There are many models proposed in the literature 
that follow this deterministic approach which are described in the literature review presented in 
the next chapter.  
The other approach is using stochastic modeling for describing the cellular processes 
which are inherently stochastic. Molecular components of cellular processes often involve low 
copy numbers and due to the complex interactions among these components, fluctuations in the 
number of molecules become very important in deciding the outcome of the associated 
biological processes. For example, stochastic events such as mutations play an important role in 
the fate of a cell, which may convert to a cancer cell from a healthy cell. Cellular differentiation 




particular cell may convert to cell of any of different types of tissues.  Other biological 
phenomena that are stochastic in nature include apoptosis and plaque formation. It is not always 
possible to identify the complete interactions and external environmental effects on the 
biochemical system. Stochastic models are developed to capture these stochastic phenomena. 
1.5 Objective 
Since the stochastic events occurring at the molecular level in a cell cycle network 
influence the response of whole organism to external stimuli, a stochastic model developed based 
on a cell cycle network, when accurately represented with the parameters will be helpful in 
predicting the population responses to the stochastic events occurring at the molecular level. One 
objective of the present work is to describe the development of a stochastic model of eukaryotic 
cell cycle and present the scope of its practical application.  
Budding yeast Saccharomyces cerevisiae is studied extensively for eukaryotic cell cycle 
research. The yeast genome is well documented, and because yeast cells are unicellular they can 
be cultured and genetically manipulated much more readily than mammalian cells. Additionally, 
yeasts are eukaryotic and their gene regulation and biochemical pathways related to cell cycle 
progression are similar to those found in higher organisms including humans. The model 
development is based on the cell cycle network of budding yeast. 
Stochastic models, even those that are simplified beyond biological reasonableness, 
contain a large number of model parameters that must be determined for the model to be of 
value. Stochastic models require data that captures fluctuations in concentrations at single cell 
level for estimating the parameters. Another approach that can be employed to estimate the 
parameters is by fitting the population distributions obtained from the model to the measured 




strategy that can be used to identify the significance of different model parameters in model 
fitting and to obtain reasonable values of the model parameters using an evolutionary 
optimization method, which is called in this work as insilico evolution.    
1.6. Thesis Organization 
This thesis contains six chapters and is organized as described below. 
Chapter 2 – Literature review of deterministic and stochastic cell cycle models is presented 
Chapter 3 – Description of stochastic chemical kinetics followed by the application of the 
stochastic formulation to develop basic cell cycle model of eukaryotic system is presented. Using 
Monte Carlo strategy, the cell cycle model is used to obtain the solution to population balance 
equations of cell growth. 
Chapter 4 – The application of stochastic cell cycle model in predicting the treatment effect of a 
chemotherapic drug on two types of cells, cancer and healthy is demonstrated. Also, a detailed 
overview of mathematical modeling in assisting the chemotherapy, various approaches for 
modeling and the associated challenges for developing accurate models are discussed. 
Chapter 5 –Methodology to systematically select model parameters from the steady state 
distributions of states of the cell cycle reaction network. Refinement of basic cell cycle model 
presented in chapter 2 to make it more suitable for budding yeast is described and the insilico 
evolution algorithm is applied to select more reasonable parameter values for the model. 
Chapter 6 – Conclusions and future directions to extend the knowledge gained through this 





CHAPTER 2. LITERATURE REVIEW 
There have been many studies dedicated to the modeling of eukaryotic cell cycle. These 
studies started with simple models that do not depend on the molecular description of the cell 
cycle. Later, when the discoveries are made about the molecular components and their 
interactions controlling the cell cycle, more detailed studies are made. These mathematical 
models of cell cycle are made to serve different goals. One of them is to understand the working 
of the cell cycle and characteristics of different phases and transitions between those phases. For 
this purpose, attempts are made to describe the cell cycle network in terms of differential 
equations and using the dynamic systems theory to understand the qualitative features of cell 
cycle such as limit cycle, hysteresis, bistability, cell size homeostasis, linking of growth to cell 
cycle progression, creation of phenotypes based on mutations at the crucial transitions which are 
controlled by checkpoints. A more sought after goal is to build comprehensive models that 
combine individual studies of sub systems of cell cycle network to predict the behavior of 
different phenotypes of cells under study. Comprehensive models of cell cycle of eukaryotes 
exist that combine many features of eukaryotic cell cycles and many species and interactions. 
Here, some of the mathematical models developed for each of the above goals are presented. 
Both deterministic and stochastic models are presented in the literature, even though most of the 
studies followed deterministic approach. First, deterministic models are discussed followed by 
stochastic models. The general mathematical formulation of deterministic models involves 
transforming the reaction network into differential equations and solving for average molecular 
concentrations.  
Mathematical modeling of cell cycle has a long history. It started with simple models of 




developed a model for fertilized frog eggs cell cycle which is described by an autonomous 
oscillatory behavior based on the levels of maturation promoting factor, a dimer of cdc2 and 
cyclin, and it consists of alternation between S and M phases. Later, models were developed by 
incorporating molecular interactions in the cell cycle. The focus was mainly on specific phases 
or transitions between these phases. Obeyesekere et al. (Obeyesekere et al., 1995) described 
control of G1 phase by a model including compounds cyclin E, cdk2 and retinoblastoma (Rb) 
protein. Kohn (Kohn, 1998) proposed a model for mammalian cell cycle with an emphasis on the 
transition at G1 – S interphase, studied the dynamics of the regulatory molecules influencing the 
transition and provided an approach for synthesizing a realistic complex molecular reaction 
network. They have followed a quasi-evolutionary approach in which functional capabilities of 
the molecular components are evaluated by adding small subsets of reactions sequentially 
towards increasing complexity to the reaction network, a method that can assist in the design and 
interpretation of experiments. Qu et al. (Qu, 2003) followed a similar approach of dividing the 
complex reaction network of molecules controlling the G1/S transition of a mammalian cell 
cycle into small modules analyzed the effect of each module on the dynamics at the G1/S 
interphase in terms of limit cycles, bistability using bifurcation analysis. Similar studies of G1/S 
transition dynamics using bifurcation theory also exist in literature (Swat et al., 2004). A more 
comprehensive cell cycle model for the S phase initiation (Barberis et al., 2007) relates the 
critical cell size requirement to the G1/S transition by using a differential equation model that 
stresses on the transport of components between nucleus and cytoplasm and the growth of cells 
in G1 phase under various nutritional conditions. 
A quantitative model for mitotic exit by down-regulation of cyclin dependent kinase 




mainly focused on verifying the molecular network controlling the mitotic exit by comparing 
deterministic model predictions with experiments. Toth et al. (Toth et al., 2007) proposed 
another cell cycle model of mitosis exit that explains the presence of two bistable switches in the 
regulatory network controlling M-phase, using phase plane analysis.  
Research group by Tyson and Novak have studied extensively eukaryotic cell cycles of 
budding yeast and fission yeast, mammalian systems. Starting with models focusing on 
molecular mechanisms for specific portions of the cell cycle, their studies extended to models of 
more comprehensive nature. A ordinary differential equations (ODE) based model by Novak et 
al. (Novak et al., 1999) explains the antagonism between cyclin dependent kinases and anaphase 
promoting complex (APC) based on the mechanism of mitotic exit of budding yeast cell cycle 
controls.  
Tyson et al. (Tyson et al., 1996) developed a cell cycle model based on a network of 
chemical reactions controlling the activities of M-phase and S-phase promoting factors to 
understand the phenomena like limit cycle oscillations, stable steady states such as cell cycle 
arrest. A deterministic model for morphogenesis checkpoint that controls the progression of cell 
cycle during the bud formation in budding yeast is presented by Ciliberto et al. (Ciliberto et al., 
2003). The model is used to predict the behavior of cells in delaying the cell cycle progression 
when external stimuli prevent the formation of bud. Bifurcation diagrams are used to analyze 
how the checkpoint governs the progression of cell cycle.  
Models are described that explain the dynamic behavior by concentrating on the entire 
network of the cell cycle. Csikasz-Nagy et al. (Csikasz-Nagy et al., 2006) presented a generic 
model of the eukaryotic cell cycle to explain the dynamic behavior of cell cycle concentrating on 




the cell cycle behavior of various organisms that include budding yeast, fission yeast, frog eggs, 
and mammalian cells. They have represented the cell cycle regulation in terms of biochemical 
reactions of the interacting molecules and built detailed ODE models through proper selection of 
rate parameters representative of organisms for which they are described. The dynamic analysis 
of the cell cycle regulation is carried out using single parameter bifurcation diagrams to show the 
linking of cell growth to cell cycle progression, creation of different phenotypes due to mutations 
and achieving of cell homeostasis by these organisms.  
Stelling and Gilles (Stelling and  Gilles, 2004) proposed a modular approach for 
modeling complex cellular regulatory networks discussed with emphasis on model structure 
selection, evaluating system dynamics and using experimental support to get realistic models. As 
an example, control of mitosis in budding yeast is described using the modular approach in terms 
of positive and negative feedback loops in the network.  Each module is represented by 
differential equations and they used bifurcation theory to demonstrate the bistability and limit 
cycle oscillations of the budding yeast cell cycle model.  
A cell cycle model of budding yeast is presented by Lovrics et al. who have used time 
scale analysis as a tool to test the cell cycle dynamics at the transition between steady states 
(Lovrics et al., 2006). This is an alternative to using cell mass as a bifurcation parameter in 
analyzing the dynamic behavior of cell cycle transitions between steady states that does not 
depend on cell mass.  
Logical methods are proposed to study the qualitative behavior of cell cycle models as an 
alternative to differential equation based models that require molecular interactions in detail and 
contain large number of parameters which need to be estimated accurately. These logical models 




model based on network of a differential equation model of a mammalian cell cycle system that 
is used to analyze cell cycle behaviors such as limit cycles, stable steady states (Faure et al., 
2006).  
 An important objective envisioned for cell cycle models is to use them to predict the 
behavior of cells to carry out various biological functions, response to various environments. The 
model should include all the crucial details of the cell cycle network to be realistic. Based on the 
understanding of the earlier cell cycle models and detailed experimental observations on yeast 
cell cycle, Tyson and Novak group came up with a most comprehensive model of eukaryotic cell 
cycle. Their first comprehensive model of the budding yeast cell cycle (Chen et al., 2000), 
developed by incorporating detailed biochemistry, genetic interactions of cell cycle control, was 
able to predict the properties of wild type cells and 50 other  phenotypes. This model had 
adequate description of G1 to S transition; however, more details of the mitotic exit are included 
in a later version of the model (Chen et al., 2004). This model was able to predict the phenotypes 
of 120 mutant strains and can predict phenotypes of new mutants, helpful for finding out 
biochemical rate constants of crucial cell cycle interactions which are difficult to measure 
experimentally. Thornton et al. presented a mathematical model that models strains lacking APC. 
The model was shown to accurately simulating APC
-
 strains and 27 other phenotypes (Thornton 
et al., 2004).  
Ribeiro and Pinto have developed a model by combining signal pathways of proteins that 
are crucial for tumor progression such as p53 pathway (important in causing apoptosis when 
abnormalities like DNA damage and abnormal growth occur in the normal cell cycle 
progression) and human cell cycle regulation pathway (Ribeiro and  Pinto, 2009). In the 




of the cell cycle proteins and solving them using analytical or numerical techniques. However, 
stochastic models differ from deterministic models.  
Stochastic models are developed to capture the fluctuations that are common in cellular 
processes. For gene networks, the concentrations of the reacting molecules will be very low, the 
fluctuations are comparable to the number of molecules of that species in the system. The 
chemical population changes as integral number of molecules and the reaction events occur as 
discreet random events. If the regulatory protein stays in low molecular concentrations, then 
fluctuations will influence the timing of the regulatory events in different cells leading to 
different fates and thus leading to heterogeneities in populations. Another example of 
stochasticity is at the “Checkpoint” pathways. Signal proteins control these regulatory events and 
the fluctuations in their expression will cause uncertainty in the timing of those events and not in 
the outcome. Thus, the duration of cell cycle for different cells varies and causes to the 
heterogeneity in the population doubling times.  
A stochastic model based on stochastic Petri net (SPN) approach is developed by Mura 
and Csikasz-Nagy (Mura and  Csikasz-Nagy, 2008) to include fluctuations to the number of 
protein molecules in the network. The ODEs from a well-defined deterministic model are 
converted to stochastic Petri net (SPN). The model predicts the behavior of wild type and many 
mutant budding yeast cells. The stochastic model predicts some characteristics that could not be 
observed by deterministic model on which it is built. It provides statistics of cell cycle duration 
and average cell mass. However, one issue with the model is it gives to negative numbers due to 
added noise to the number of molecules in less abundance. Their model considers does not 





For biochemical systems involving molecules in low numbers, Langevin-type equations 
are used which give rise to stochastic differential equations in the model formulation as in 
another work (Steuer, 2004). It is proposed that the system of differential equation, when 
introduced noise, is not merely a small deviation from the deterministic behavior rather it will 
have a different dynamic behavior. One issue with this type of models is that they are applicable 
only when the molecules exist in large numbers.  
 Braunewell and  Bornholdt investigated the stability of a cell cycle model of budding 
yeast in the presence of intrinsic noise in the gene regulatory network (Braunewell and  
Bornholdt, 2007). Their stochastic model uses a generalization of Boolean network dynamics 
(Thomas, 1973). 
Some stochastic models use stochastic formulation of chemical kinetics for the 
biochemical reactions representing the cell cycle network. Stochastic approach to chemical 
kinetics is described in the later chapters of this report. The evolution of the reacting system in 
terms of the discreet reaction events is a discreet markov process (Gillespie, 1992) and is 
described by the chemical master equation (Gillespie, 1992). The solution to the CME is 
calculated using SSA presented by Gillespie (Gillespie, 1976). The stochastic chemical kinetics 
approach is discussed in the next chapter of this report. 
Arkin et al. (Arkin et al., 1998) emphasizes stochasticity in gene expression by studying 
phase Lambda lysis – lysogeny decision circuit. Although, this model is not based on eukaryotic 
cell cycle, the stochastic formulation of chemical kinetics used here is employed in other 
stochastic models of eukaryotic cell cycles. 
A software program is developed to simulate biochemical systems using stochastic 




They have tested the computational capabilities of the Gillespie‟s algorithm with their model 
taking the examples of two cellular processes, one with large number of reactions and another 
with small number of reactions. One limitation is the reaction set in any network, for this 
program to be implemented, should be either first order or second order. 
A stochastic model based on a probabilistic Boolean network on the protein interaction 
network of the yeast cell cycle is presented in another work (Zhang et al., 2006). Stochasticity is 
introduced by adding noise in terms of a temperature like parameter to the nodes representing 
proteins or protein complexes in the Boolean network. They have found out that the biological 
pathway, which is a cell cycle sequence of protein states, is stable for stochastic fluctuations and 
for large noise, the network behaves randomly. Thus, they demonstrate that the network of 
interacting proteins is robust under noise. 
Sveiczer et al. present a stochastic model for fission yeast cell cycle based on a 
deterministic model (Sveiczer et al., 2001). They have introduced stochasticity by incorporating 
asymmetry of cell sizes at the time of division and assuming unequal volumes for nuclei of 
newly divided cells. The model is able to predict the population distribution of wild type cells.  
In another work, stochasticity is introduced into a deterministic model by adding 
deviations to the deterministic rate of protein concentrations (Ullah and  Wolkenhauer, 2009). 
Thus, all the biochemical reactions rates and concentrations of proteins are described by 
stochastic variables and the mathematical model is expressed in terms of stochastic differential 
equations. 






CHAPTER 3. BASIC CELL CYCLE MODEL USING STOCHASTIC APPROACH 
3.1. Stochastic Chemical Kinetics 
 In the stochastic approach, probability theory is applied to describe the kinetics of the 
stochastic processes associated with the biochemical network. In the stochastic formulation, the 
reaction propensity or the probability for that reaction to occur depends on the current states of 
the system described by the number of molecules of each species in the network. The states of 
the system evolve according to the discrete Markov process governed by a probability density 
function which follows a chemical master equation (CME) (Gillespie, 1992). 
CME is a deterministic differential equation in the probability of the system being in any 
state of the system. Generally, reactions systems exist in many possible states and this leads to as 
many differential equations in probability as there are possible states of the system. 
The CME is given by  
             
  
                                              
 
   
 
           = state of the system, in terms of the number of molecules of „N‟ reacting species  
             = the probability that the system will be in state „x‟ at time „t‟ starting with an 
initial state x0 at time t0. 
                                                                 
= Probability that a µ
th
 reaction will occur in (t, t+dt), given that the system is in the state 
„x‟ at time t 
   is the reaction propensity of µ
th
 reaction, which is stochastic equivalent of reaction rate 
constant.      = Probability that a particular combination of reactant molecules of µ
th
 reaction 




   = number of distinct molecular combinations of the reactants of the µ
th
 reaction. For 
example, for a first order reaction,    simply equals the number of reactant molecules N, for a 
second order reaction it equals 
      
  
, etc. 
Clearly, the probability of reaction occurring depends on the state of the system given by 
the number of molecules of the reacting species. A detailed derivation of CME is presented in 
(Gillespie, 1992). 
According to the CME, the state of the system at any time is a random vector that follows 
the cumulative probability distribution evolving from the CME. However, analytical solutions of 
the CME are possible only for simple cases. McQuarrie (1967) present examples of various 
simple reacting systems for which analytical solutions are possible (McQuarrie, 1967). The 
authors review the approach of Master equation for chemical kinetics. In most of the reaction 
systems, numerical solutions are desired for the CME. One such method to exactly simulate the 
stochastic behavior of the reaction system according to the CME is presented in the form of exact 
stochastic simulation algorithm (SSA) by Gillespie (1976) (Gillespie, 1976). Through this 
method, it is possible to deduce the time trajectories of reacting species resulting from discreet 
molecular events. The algorithm is based on a joint probability function that determines the 
reaction that occurs next and the time at which it occurs in a discreet stochastic process. 
The joint probability function is given by, 
                 Probability that, given the state x at time t, the next reaction will occur in the 
infinitesimal time interval (t + τ, t + τ + d τ), and it will be µ
th
 reaction. 
                    ) 
Where,       
 
   
      
 





There are various numerical algorithms available that are exact or approximate to 
simulate the time course trajectories of the reacting system. Gillespie (Gillespie, 1976, 1977) 
presents two methods to simulate the SSA which are direct method and next reaction method. 
3.1.1. Direct Method 
In the combined probability density function, the probability of any reaction to occur 
depends on the reaction propensity and on distinct combinations of the reactant molecules. The 
higher the reaction propensity is the more likely it is that the reaction will happen next. The 
algorithm for this method is presented in Table 1. It starts with the initialization of the state of 
the system, i.e. number of molecules of each species, cell mass etc. Reaction propensities are 
calculated for each reaction based on the current state of the system. Random numbers are 
generated using reaction propensities to determine the next occurring reaction and the time of its 
occurrence. State of the system is updated to reflect the occurrence of a selected reaction event. 
The time interval between two successive state updates is called the interval of quiescence during 
which the state of the system is assumed not changing. Since the time steps are relatively small, 
any changes in the state like cell mass will not affect the propensities much in the interval of 
quiescence. This procedure of selecting random time and reaction followed by state update 
continues till the end of the simulation and the time course trajectory of the state of the system is 
obtained. 
3.1.2 First Reaction Method 
This is exactly same as the direct method, but the implementation to obtain the solution of SSA 
is different. For each of the reactions, time of occurrence is calculated as if no other occurred 
first. The difference between the two methods is that more random numbers are used with the 




Table 1: Direct Method - Algorithm 
Step 0:  
Initialize the state            
Input the values of the propensities,     
Initialize the time t = t0 
Step 1:  
Calculate                   
Calculate         
 
   
 
Step 2: Generate uniformly distributed random numbers in [0,1], r1 and r2 
Select    
 
  
           
Select µ as an integer satisfying ,    
   
            
 
     
Step 3:  
Advance t = t + τ 
Update the state of the system according to the execution of reaction µ. 
Repeat step 1 to step 3 until final time. 
 
 
Table 2: First Reaction Method - Algorithm 
Step 0:  
Initialize the state            
Input the values of the propensities,     
Initialize the time t = t0 
Step 1:  
Calculate the reaction propensities,             
Step 2:  
Select M random numbers r1,…rM from the uniform distribution [0,1] 
    
      
  
          
Select   such that                 
Select µ as the index         for which    is minimum. 
Step 3:  
Advance t = t + τ 
Update the state of the system according to the execution of reaction µ. 





These exact stochastic simulation algorithms will be efficient when used for reaction 
systems with small set of reactions and reacting species. The biochemical reaction networks used 
to represent the intracellular processes contain large number of reactions and components. For 
such cases, exact simulation algorithms become computationally expensive. There are 
approximate algorithms available that improve the computational speeds.  
Gibson and Bruck (2000) present next reaction method that is developed based on first 
reaction method to reduce the use of random numbers and to reduce the computational load by 
introducing the concept of priority index queue (Gibson and  Bruck, 2000). Number of 
calculations of the reaction propensities is reduced drastically with the use of cleaver data storage 
structures, by modifying and reusing the values of propensities in the priority queue.  
An optimized direct method is used by Cao et al. (2004) (Cao et al., 2004) which is an 
optimized version of the direct method proposed by Gillespie (1977) (Gillespie, 1977). The 
search depth for identifying the next reaction that occurs in the algorithm is reduced by arranging 
the reactions in decreasing order of the number of times each reaction fires in a time span of 
interest. 
Gillespie (Gillespie, 2001)  presented an explicit tau-leaping method according to which 
number of times each of the reaction fires is decided by a poisson random variable, in a leap or 
subinterval of time that does not result in much changes to the reaction propensities. The method 
is explicit in the sense that the propensities for the next time step are evaluated based on the 
current state. This method is advantageous when there are moderately large numbers of reacting 
species. As each reaction event may result in the change of only one or two molecules, a large 




The selection criterion that does not result in much change in the propensities is improved in 
another approach (Gillespie and  Petzold, 2003). 
Binomial leap methods for stochastic chemical kinetics use binomial random variable 
instead of Poisson random variable for determining the number of firings of each reaction in a 
time leap (Tian and  Burrage, 2004). This way, possible reaction firings can be restricted and 
negative molecular numbers are avoided when large time steps are used. 
By characterizing some of the reactions as critical reactions for which the reacting 
species are in the danger of exhaustion, a modified tau-leap method is used to avoid negative 
molecular numbers during the simulation (Cao et al., 2005b). It is proposed as an improvement 
over the binomial leap methods. 
To avoid the instability for stiff reaction systems at larger time steps of the explicit tau-
leaping method, an implicit tau-leaping method is proposed that has greater numerical stability 
(Rathinam et al., 2003). In the implicit version, the propensities are evaluated based on the 
estimated future state of the system that ensures stability. Limitation of these tau-leap methods is 
that they require the values of propensity functions to be approximately constant. This 
requirement is realizable only when the species population is large compared to 1. 
In the context of the limitations of tau-leap methods in applying to systems with low copy 
number of molecules, hybrid methods have been proposed. Hybrid methods combine the 
deterministic regimes expressed by chemical Langevin equation with the discreet stochastic 
regime expressed by SSA. Hybrid methods account for multiscale nature of reacting systems. 
Multiscale phenomena occur at time scales and population scale. On time scale, some reactions 
occur very fast and always will be in equilibrium state while slow reactions dominate the 




dealt using discreet approach whereas some species exist in large numbers that can be accurately 
represented by deterministic approach.  
A simplification to the stochastic kinetic model is made by applying quasi steady state 
approximation (QSSA) to the SSA (Rao and  Arkin, 2003). QSSA assumes the rates of change of 
intermediate species to be zero for time scales of interest. Using QSSA, they have reduced the 
complexity of the model by reducing the number of reactions and molecular species that have 
fast dynamics and are not of much interest. 
Cao et al. (Cao et al., 2005a) describe a partial equilibrium assumption that executes the 
SSA for slow reactions with the propensity functions calculated based on the partial equilibrium 
values of the fast species molecular concentrations. This method avoids the expensive simulation 
of the fast reactions. 
All these exact or approximate algorithms greatly help to simulate the stochastic behavior 
of many biochemical systems of interest. 
3.1.3. Monte Carlo Strategy 
Using any of the above algorithms, it is possible to traverse along the evolving state of 
the system by following similar procedure. The procedure simulates a sequence of state 
dependent random variables which is equivalent to the evolution of the state of the biochemical 
reaction system of the cell cycle. Starting with an initial state, time for the next reaction and the 
index of the next reaction is generated in terms of the state of the system and these two random 
variables determine the next updated state of the system. This procedure is continued till a 
desired final value of time.  
Under identical initial conditions, different independent stochastic simulations will give 




distributions of states. The strategy is to repeat stochastic simulation up to a final time, large 
number of times and the desired properties obtained in each trial are summarized to deduce the 
distribution of properties.  
3.2. Stochastic Cell Cycle Model 
3.2.1. Solution to Population Balance Models Using Cell Cycle Model  
One interest in obtaining the population distributions of cell populations is in the 
chemotherapic drug applications where researchers want to study the response of cell 
populations to various drug actions. Due to the heterogeneity among the cell population, each 
cell responds differently to a given action of chemotherapic drug and thus a mathematical model 
to describe the population behavior of cells will be useful to estimate the curing potential of a 
drug. Population balance models are used to deduce the population distribution of properties of 
various particulate systems. 
Population balance models (PBM) are number balances on population of particles which 
include biological cells. Population balance models for describing biological cell populations are 
different from those used for other particulate systems such as crystallizers, bubbles or aerosols. 
Dependent variable of a population balance is the distribution of states (Eakman, 1966; 
Fredrickson, 1967; Ramkrishna, 2000; Hjortso, 2006). For a population of cells that follow a cell 
cycle model of biochemical network of cell cycle proteins, the distribution of states is a 
probability distribution indicating the frequency of cells with a given cell mass and a given 
number of molecules of the molecular components of the cell cycle network which may involve 
hundreds or even thousands of metabolites and similarly large complex biochemical reactions. 
This leads to a large number of state variables in the population balance equations the solutions 




methods and methods of weighted residuals will work well only for low dimensional problems. 
Monte Carlo simulations are suggested as an alternative method to obtain the solution of 
population balance problems of high dimensionality (Shah et al., 1976; Shah et al., 1977; 
Ramkrishna, 2000). Previously, Sherpa and Hjortso (unpublished work) described how the 
distribution of cell states can be obtained from the Monte Carlo simulations of a cell cycle model 
using stochastic chemical kinetics approach. The implementation and solution of this cell cycle 
model is presented here. 
3.2.2. Description of the Basic Cell Cycle Model 
 A simple model adapted from the deterministic model of Tyson and Novak (Tyson, 2000) 
and not specific to any organism is used as the biochemical network representing the interactions 
among the proteins involved in cell cycle regulatory system.  
The cell cycle network is shown in Fig. 1 and it is not specific to any particular organism. 
Several cyclin-kinase complexes that normally take part in the chosen model are lumped into a 
pseudo compound, cyclin/Cdk as shown in Fig. 1. Activated cyclin/Cdk activates conversion of 
APC to its inactive form while active APC activates degradation of cyclin, thereby removing the 
activated cyclin/Cdk complex. Increased accumulation of cyclin/Cdk initiates production of an 
activator protein which activates conversion of APC from the inactive form to the active form.  
The cell cycle model contains two checkpoints or irreversible transition points. The first 
checkpoint is called the “start event” and is triggered when the number of molecules of 
cyclin/Cdk exceeds a specified threshold value. This event occurs when the cell switches to a 
state with a high amount of cyclin/Cdk and corresponds roughly to the transition from the G1 – 
phase to the S – phase. The second checkpoint is passed only if the cell has passed the start event 




corresponds roughly to the state after DNA replication has finished and the chromosomes are 
aligned on the mitotic spindle. In this model it signifies cell division. 
 
Figure 1: Schematic of the eukaryotic cell cycle network. (Sherpa and Hjortsø – unpublished) 
 
Individual reactions and expressions for propensities are shown in Table 3. The binding 
between cyclin and Cdk is assumed fast such that rate of cyclin/cdk formation is equal to the rate 
of cyclin synthesis. Degradation of cyclin/Cdk is modeled as two parallel reactions, one which is 
constitutive another which is activated by active APC. The model does not include reactions for 
synthesis and turnover of Cdk and APC as both are assumed to be maintained at constant 
concentrations in the cell through the cell cycle.  
3.2.3. Implementation and Solution of the Cell Cycle Model 
The model contains 4 discreet variables, number of molecules per volume of cyclin/Cdk 
(X), of active and inactive APC (Ya, Yi) and of activator protein (A) and one deterministic and 
continuous variable, the cell mass (m). Formation of cyclin/Cdk is assumed to be rapid compared 





Table 3: The reactions of the eukaryotic cell cycle model 
 „m‟ is the cell mass, X – number of molecules per volume of cyclin/Cdk; Ya – of active APC; Yi – 
of inactive APC; A – activator protein 
Reaction 
Number 
Stoichiometry Reaction propensity, cn Reactant combinations, 
hn 
1                      
2                  
3                       
4                         
   
    
     
 
   
5                         
   
  
    
   
     
 
   
6                    
     
  
  
       
        
 
  
7                         
 
It is assumed that all the cells divide continuously without considering dormant cells, 
differentiated cells and mature cells. Cell mass is the only continuous state variable and it is 
assumed to be growing according to first order growth kinetics and it is independent of the 
values of the discreet state variables.  Cell mass increases exponentially with time as  
                    
Where,      is the initial cell mass at time   ;   – specific growth rate. 
Due to the stochastic nature of the cell cycle oscillator in this model, there is always a 
possibility that the trajectory of the system can escape from the oscillatory state. In that case, cell 
never passes the second checkpoint and therefore never divides. Consequently, cell mass 
increases without bounds and a cell is assumed dead when its mass exceeds a specified value. In 
one way, it represents the natural death that occurs in cells due to errors in the regulatory system. 
Hence, cell deaths due to any drug action on the cell population will be in addition to the natural 




Asymmetric division of mother cells is considered using a unimodal probability 
distribution function as one source of cell cycle variability. Cell mass is assumed to partition 
according to the function        at the time of cell division, where          is the 
probability that a dividing  cell of mass M will give rise to a new cell with mass between m and 
m+dm. 




                                                                             
          
             
 
         
 
                       
                                                                       
  
The function is a bell shaped curve situated between a minimum possible cell mass     
and          ,the maximum possible cell mass that can result from division of a cell with 
mass M. Perfect binary fission is a special case of this distribution. The concentrations of all 
other model variables are assumed preserved in a division, i.e. the number of molecules of each 
of the discrete variables does not change. 
3.2.4. Monte Carlo Solution for Population Distributions 
The reactions among the four discreet variables are modeled using stochastic chemical 
kinetics. Gillespie‟s algorithm for direct method described in the previous chapter is used to 
simulate the time course trajectory of state of the system in the cell cycle. Monte Carlo strategy 
is used to obtain the population distribution. Because of the stochastic nature of the model, 
different simulations of the cell cycle model with same initial state will have different outcomes 
and the distribution of the cell states follows the probability distribution given by the CME for 
the assumed cell cycle biochemical network. 
All the parameters and state variables are given arbitrary units as the model does not 




model parameters are systematically tuned to obtain reasonable oscillatory dynamics 
qualitatively resembling eukaryotic cell cycle.  
The stochastic model for simulating the cell cycle progression of a single cell is modified 
to include multiple cells at the start of the simulations. The total number of molecules of each 
species involved in the cell cycle is specified for all the cells as random initial states of the cell 
population. By using these random initial states for different cells, another source of extrinsic 
heterogeneity of cell population is included in addition to the asymmetric division of cell mass. 
As time increases, cells continuously undergo division or death thereby changing the size of the 
population. Thus, these simulations once started can be viewed as cell population that is 
changing over time. From these simulations, it is possible to obtain the time trajectories of total 




CHAPTER 4. APPLICATION OF STOCHASTIC CELL CYCLE MODEL IN 
CHEMOTHERAPY 
4.1. Introduction 
Chemotherapy is the usual treatment strategy in the earlier stages of tumor development 
or after the surgery. Conventional chemotherapy involves strategic administration of drug that 
kills tumor with less toxicity to normal cell tissues (Sanga et al., 2006). Chemotherapic drugs are 
mainly classified as cell cycle non-specific, cell cycle specific drugs. Cell cycle specific drugs 
facilitate the design of treatment strategies that exploit the difference in the cell cycle kinetics of 
cancer cells and healthy cells to selectively kill cancer cells. Thus, there has been growing 
interest in the development of more cell cycle specific drugs in treating tumors.  
 There are many challenges and goals that need to be addressed for making the field of 
chemotherapy successful. Among these challenges, toxicity to the normal cells receiving the 
same treatment is a primary concern. Since healthy cells and cancer cells both live in the same 
microenvironment utilizing the nutrients, application of chemotherapy targeting cancer cells will 
also affect healthy cells which leads to varieties of toxicities. Thus the primary challenge of 
chemotherapy is to kill cancer cells with minimal toxic effects to normal tissues. Both 
biochemical and kinetic resistance to the drugs affect treatment outcome (Norton and  Simon, 
1986) which should be handled carefully. Biochemical resistance is the resistance developed by 
the tumor cells to the acting chemotherapic drug. Kinetic resistance is observed for phase 
specific drugs which are only effective in particular phases of the cell cycle and are ineffective in 
the other phases. Multiple drug resistance is another problem of chemotherapy where a single 
mutated gene results in resistance to many drugs of different biological composition and 
configurations and understanding its evolution and control is another important challenge 




before it reaches its target sites on tumors and a successful delivery of the drug to its target 
requires detailed understanding of the effect of these barriers which is separately studied as drug 
pharmacokinetics. Individuals have different drug pharmacokinetic properties and variations in 
the immune systems which result in differences in birth and death rates of cells, evolution of 
drug resistance. Due to this highly heterogeneous nature of the tumors among individuals, same 
type of drug and its administration strategy may not work well for all the individuals in a similar 
manner and hence chemotherapic strategies should be tailored to each patient. Even for a given 
patient, due to the inherent heterogeneities among the tumor cells, not all the cells respond 
uniquely to given drug and thus it is important to identify the best treatment strategy that is 
characterized by the dose, exposure time, periodic or continuous administration of the drug 
without inducing more toxicity to the patient. Using multiple drugs is usual practice due to 
toxicity considerations and due to evolving resistance to a single drug, many novel, minimally 
cross-resistant drugs have been identified. Identifying the best combination of these drugs and 
their administration regimens is crucial for achieving best results from the treatment which is 
difficult to accomplish by experience from clinical practice alone. During the drug development 
stage, probability of cure of a newly developed drug should be known before deciding on its 
introduction into the market. Millions of dollars are spent by pharmaceutical companies on costly 
clinical trials and lab experiments to screen potential drug candidates with high probability to 
achieve cure. However, the drug development process is considered to be highly inefficient due 
to the high failure rate (>75%) of most of the drug candidates (Sanga et al., 2006). 
 Mathematical modeling and bio computation in combination with experiments and 
clinical trials is considered to be a valuable tool by the cancer research community to address the 




generating predictions about the optimum treatment strategies to achieve treatment objectives 
which can be tested through accurately designed experimental and clinical studies  (Goldie and  
Coldman, 1986). Thus, Time, money, energy, animals can be spent on conducting more 
statistically significant clinical trials and experiments.  
In this chapter, application of the stochastic cell cycle model, described in the previous 
chapter, in evaluating the effect of scheduling and doses of cell cycle phase specific drugs on 
tumor cells and healthy cells is presented. The stochastic model described in the previous chapter 
for obtaining the distributions for cell population based on the dynamics at single cell level is 
used as tumor growth model. The chemotherapic model based on the stochastic cell cycle model 
formulation in its preliminary stage is aimed at a long term goal of addressing the previously 
mentioned challenges hampering the progress of chemotherapy field.  
In the next section, general features of chemotherapic models and a review of previous 
models in literature is presented along with an outline of the present model development. It is 
followed by a section on the development of chemotherapic model based on cell cycle model is 
described and the simulation methodology for evaluating various chemotherapic strategies is 
delineated. Results from drug testing simulations are presented and discussed followed by 
conclusions. 
4.2. Literature Review on Mathematical Models in Chemotherapy 
Mathematical approach for chemotherapy has a long history. Even though theories were 
formed long ago, due to the lack of sufficient computational power and experimental and clinical 
data for tumor growth, research in this field gained momentum only since late 90s. With the 
advent of super computing power and of high end experimental techniques to trace the tumors 




predict response to multiple drugs, tailor treatments to individuals by integrating details at 
multiple scales (Gardner and  Fernandes, 2003). A pictorial representation of multiple scales at 
which chemotherapy modules are developed is presented in other studies (Sanga et al., 2006; 
Ribeiro and  Pinto, 2009). Models exist in literature, developed for individual modules and also 
those developed for integrating different modules.  References to different mathematical models 
involved in the description of tumor growth for cancer chemotherapy are found in (Swan, 1990; 
Gardner and  Fernandes, 2003; Sanga et al., 2006; Venkatasubramanian et al., 2008; Swierniak 
et al., 2009). These models are classified in many ways –deterministic and stochastic; spatially 
homogeneous and heterogeneous; cell cycle specific and non-specific. Most of the mathematical 
models follow deterministic approach where behavior of cancer cells is averaged rather than 
considering individual variations among the cells which cannot be neglected when describing the 
cancer phenomena. Stochastic models are developed to address the randomness prevailing in the 
origin and progression of cancer. Spatially heterogeneous models focus on the detailed 
vasculature in the tumors and on the distribution of nutrients, drugs in the highly irregular 
structures inside the tumor. A detailed review of modeling approach for spatial variations is 
given in (Sanga et al., 2006). Cell cycle specific models are specifically designed to facilitate the 
testing of cell cycle specific drugs.  
Mathematical models in chemotherapy differ in the way they include the details to 
represent the tumor systems and the effect of chemotherapy viz. growth pattern of tumors, drug 
pharmacokinetics, drug resistance, toxicity, type of killing effect of the drug on tumor cells, cell 
cycle specificity, combined action of multiple drugs and also they differ in the goals they are 




models, one is to describe the growth of tumor and the other is to incorporate the effect of drug 
that kills some or all of these cancer cells.  
4.2.1. Describing the Growth of Tumor 
Models representing tumor growth can be broadly classified into two categories: 
homogeneous models that consider tumor as homogeneous population of cells and models that 
consider spatial heterogeneity of tumors (Venkatasubramanian et al., 2008).  
In the literature, many models are found that use homogeneous assumptions. There are 
simple exponential, Gompertzian and logistic growth models that does not relate to the biological 
details of the tumor system (Norton and  Simon, 1986; Martin et al., 1992; Iliadis and  Barbolosi, 
2000), (Gardner, 2002). Tumors contain relatively less number of cancer cells immediately after 
the surgery or in early stages of cancer and the tumor growth is approximately exponential. As 
the tumor grows larger in size as in late stage of the cancer, transport limitations of blood supply 
cause the cell population to reach a plateau after certain size which is generally modeled using 
Gompertz and logistic equations. Multiple compartmental models differentiate various phases of 
the cell cycle into homogeneous compartments to obtain cell population dynamics. Different 
phases of the cell cycle viz. G0, G1, S, G2, M and their sub phases and a separately added death 
phase are denoted by these compartments for cell cycle specific models. Cell cycle non-specific 
models generally use proliferating and quiescent compartments. The progression of the cell 
through the compartments is described by parameters such as transition rates between the 
compartments, cell birth rates and decay rates, cell kill rates due to drugs. Depending on whether 
these are parameters are fixed or variable, compartments may be deterministic or probabilistic. 
Some studies use both deterministic and probabilistic compartments in their models (Dibrov et 




the chemotherapy. For example, models that consider only cytotoxic drug propose two 
compartment models, whereas those including the additional cytostatic drug or recruiting agent 
propose three compartmental models (Ledzewicz and  Schattler, 2002).  
Another approach is to use cell population balance models (PBM) which can be 
structured or unstructured for describing tumor growth. For unstructured population balance 
models, cells will undergo transitions at different phases or stages at prespecified rates. 
Unstructured population balance models result in ODEs which may not represent the cell cycle 
phase delays (Gaffney, 2004). Structured models of cell population dynamics account for the 
variability among the cells in age, mass, RNA content, volume and other physically measurable 
properties (Webb, 1990). The transition rates between the phases depend on the structured 
variable and these models generally result in partial differential equations or integro-partial 
differential equations in the structured variables. Webb (1990) developed a cell cycle specific 
model with age and size structured population balance model. Brikci et al. (2008) (Brikci et al., 
2008) used age and cyclin structured PBM to simulate the growth of cancer and normal cells in 
parallel using two compartments – proliferating and quiescent. Some growth models are 
developed based on theory of branching processes (Goldie and  Coldman, 1983; Day, 1986). 
 Due to the transport limitations of oxygen and nutrients, tumors form a heterogeneous 
mass that have wide variations in space. Modeling these factors interacting in spatial domain is 
considered in some studies as a more realistic approach than homogeneous assumption of the 
tumor mass (Sanga et al., 2006; Swierniak et al., 2009). These models consider transport effects 
of drugs, nutrients in the micro environment surrounding cells. The microenvironment 
surrounding these cells comprises of mass of other cancer cells, a network of blood vessels that 




vasculature. Some studies do not incorporate tumor vasculature in their models which are 
referred to as avascular tumor growth models (Venkatasubramanian et al. 2008 and the 
references therein) and other studies include vasculature in their models (Sanga et al., 2006). 
More complex models describe tumor growth by incorporating angiogenesis, process by which 
new blood vessels are formed from the existing vasculature (Sanga et al. 2006 and the references 
therein). Generally these tumor models are described mathematically in terms of partial 
differential, ordinary differential, and algebraic equations and solved using numerical 
simulations. Stamatakos et al. developed a 3D model for tumor growth based on the 3D structure 
of the tumor and functional gene data.  
Another approach to describe the growth of the cells is using mechanistic models that 
describe the growth of individual tumors in relation to biochemical network of various proteins 
and genes that are involved in cell cycle regulatory network errors of which are linked to the 
origin and progression of cancer (Chappell et al., 2008; Ribeiro and  Pinto, 2009). 
4.2.2. Describing the Effect of Drug on Cancer Cells 
When it comes to the cell kill due to drug, there are many ways it is implemented. 
Response of cancer cells in monolayer cultures (in vitro) is different to that in vivo. The 
interaction of drug with blood and bodily environment into which it is injected plays a crucial 
role in the final response of cancer cells to drug. Effect of micro and macro environment 
surrounding cells on drug is studied as drug pharmacokinetics and the effect of drug on cancer 
cells is referred to as drug pharmacodynamics.  
Pharmacodynamics (PD) 
When PD is modeled, an additional cell kill term is added to the tumor growth model. 




Norton-Simon type model, or a bilinear law that multiplies both the drug concentration and cell 
concentration. According to log-kill concept, a given dose kills a constant proportion of a tumor 
cell population irrespective of the size of the tumor (Ledzewicz and  Schattler, 2002). Norton-
Simon‟s hypothesis (Norton and  Simon, 1986) says that rate of cell kill is also proportional to 
the growth rate of the unperturbed tumor according to which proportion of tumor cells killed by a 
given dose of drug decreases with increase in size of the tumor. Cell kill terms of bilinear 
expression (Ledzewicz and  Schattler, 2007; Ribeiro and  Pinto, 2009) are considered mainly 
when drug pharmacokinetics cause changes in drug concentration with time. Effect of cell kill is 
included in these terms in the form of cell kill rates. The relationship between the cell kill effect 
and the drug dose are given by dose response curves. The dose is obtained from the “Area under 
the concentration versus time of exposure of the drug (AUC)” curve to measure the cell kill 
effect of the drug. AUC gives the cumulative dose of the drug during the total drug exposure 
time. Other than dose response curves, empirical models are also used to relate the cell kill effect 
to the drug dose. A simplified relationship considers cell kill effect to be “on- off” type, that 
results in killing of all the cells during the drug effective period (Webb 1990, Augur 1988). Hill 
model and Exponential kill models (Goldie and  Coldman, 1983; Gardner, 2000) are often used 
for this purpose. In Ledzewicz & Schattler (2005), PD is given by Emax, Sigmoidal relations. 
More realistic functions which describe the saturation effects include Michaelis–Menten formula 
which is more suitable for fast acting drugs that saturate at high concentrations or the sigmoid 
function that more accurately approximates the effectiveness at both lower and higher 
concentrations of the drug (Swierniak et al., 2009). According to above relations, response to the 
chemotherapic drug by using the value of dose obtained from AUC will be same for any amount 




drug, cell cycle time, duration and concentration of the drug exposure at the site of action, level 
of drug resistance affect the shape of the dose-response curves (Gardner, 2000). By incorporating 
such factors, Laveuser et al. (1998) (Levasseur et al., 1998) proposed Modified Hill model and 
Gardner (2002) (Gardner, 2002) used a modified exponential kill model both resulting in 
sigmoidal dose response curves. Some researchers speculate that dose of the drug may not be the 
proper measure to introduce the effect of cell kill and they propose peak DNA bound drug 
concentration to replace the total dose of the drug (Sanga et al., 2006). 
Pharmacokinetics (PK) 
Intensity of the effect of the drug is influenced by the ease with which it can be delivered 
to the target. Drug pharmacokinetics plays a crucial role in this. Drug has to overcome many 
barriers before it is delivered to the target location. The cumulative effect of these barriers is 
described by compartmental modeling (Godfrey, 1983; Jacquez, 1996) in which different 
components are interconnected in the overall process of drug delivery to the target from the drug 
intake into the extra cellular environment. Various components that are generally represented by 
the compartments in pharmacokinetic models include lesion interstitium, cell membranes, 
intracellular organelles, blood-brain barrier and other barriers obstructing successful drug 
delivery to the target. One of these compartments gives the concentration at the tumor site and it 
appears as the drug concentration in PD equations. 
Different multi-compartmental models are proposed that are either linear or non-linear 
PK models. Simple linear models are proposed in the form of first order linear differential 
equations. An accurate representation is done by introducing nonlinearities into the models. 
Simple nonlinearities are introduced in the form of bilinear systems (Ledzewicz and  Schattler, 




Venkatasubramanian et al. (2008) use both linear and non-linear pharmacokinetics in a three 
compartmental model: Central compartment represents blood plasma and two peripheral 
compartments represent organs and tissues that have poor distribution of drug. Ribeiro (2009) 
use a three compartment model that represents blood, extracellular environment and tumor cell 
as the compartments. 
Drug Resistance 
Drug resistance is another phenomenon by which cancer cells evade the action of drug 
and it is an important challenge to be overcome before making chemotherapy successful. 
Mutations to crucial genes involved in the cell cycle regulatory pathways such as DNA repair, 
apoptosis and to those involved in the drug related activities like absorption, distribution, 
metabolism, excretion are considered to be main reason for the evolution of drug resistance. The 
drug resistance is described by a single, random irreversible mutation (or point mutation) 
(Coldman and  Murray, 2000) to a crucial gene or by reversible multistep mechanism of gene 
amplification through which multiple copies of the mutated gene are acquired in leading to 
different levels of drug resistance. A general approach in point mutation models is to divide the 
cell population into different clones each having a different type of mutated single gene along 
with the non-mutated drug sensitive cells. During the cell growth, cells from one clonal category 
to another transform through single random mutation event characterized by mutational 
probability rates. Drug resistance models built based on the mutational probability rates obtained 
from patient biopsies (Gardner, 2002) will help to describe this phenomenon accurately. For 
describing gene amplification, a similar approach is followed where cells are categorized 
according to the number of mutated gene copies and reversible transformation of cells from one 




4.2.3. Previous Models of Chemotherapy 
An extensive literature review of studies for chemotherapic models is presented in the 
Appendix E. Some of the studies relevant to the present work are mentioned here. Mathematical 
models that describe the controlling and regulatory mechanisms at the single cell level will help 
to explain the patient specific treatment effect of drugs. In response to treatment, cells may 
undergo apoptosis or develop defense mechanisms such as drug resistance or differentiation. If a 
mathematical model is developed based on these regulatory processes at the single cell level to 
obtain the population characteristics, if it is tractable computationally or mathematically, will 
greatly aid in the patient tailored treatment. Ribeiro & Pinto (2009) has developed a deterministic 
biochemical network based multi-compartmental model that depends on the molecular 
mechanisms of cancer development, neglecting drug resistance, cell cycle specificity and toxicity 
to normal cells. The deterministic approach follows as forming the differential equations for 
various proteins involved and solving them analytically or numerically assuming average 
concentrations. They combined signal pathways of proteins that are crucial for tumor progression 
such as p53 pathway (important in causing apoptosis when abnormalities like DNA damage and 
abnormal growth occur in the normal cell cycle progression), targeted by drug action, and cell 
cycle regulation pathway. They have combined this network module with a compartmental 
PK/PD model following a multi-scale integrative approach. Another network based deterministic 
model is presented by Chappel et al. (2008) (Chappell et al., 2008) a single drug kinetics is 
linked directly to the cell cycle reaction network and thus avoiding the necessity for using 
separate PD model. Without considering drug resistance, toxicity they have combined this 
complete network dynamics with PK following an integrated approach for evaluating the effect 




4.2.4. Present Model 
The stochastic cell cycle model is combined with PD and PK laws to form an integrated 
chemotherapic model. The model is formulated to test the effect of multiple cell cycle phase 
specific drugs. The model formulation facilitates the evaluation of multiple toxicities in response 
to treatment along with tumor response to chemotherapic drugs. As more information becomes 
available about specific genes involved in oncogenesis and drug responses and as methods to 
measure cell kinetics become feasible to perform in a clinical setting, it appears that a network 
based model can be used to account for individual patient specific models. In contrast to the 
network based models mentioned earlier (Chappell et al., 2008; Ribeiro and  Pinto, 2009) which 
are deterministic, a stochastic approach is to account for variable cell cycle kinetics of cancer 
cells. The intrinsic and extrinsic heterogeneities that are commonly observed in cancer cell 
population can be handled suitably using stochastic approach. The development of the overall 
chemotherapic model is described in the next section.  
4.3. Using the Stochastic Model for Drug Screening and Efficacy Tests 
It was discussed earlier about obtaining the growth of cell population based on Monte 
Carlo simulation of the stochastic cell cycle model. Here, the same model is used to obtain the 
growth of tumor cells and healthy cells. Repeating simulations with different initial number of 
tumor cells and their random initial states, it is possible to simulate the intra and inter 
heterogeneities in tumor growth among patients. By combining these simulations with cell kill 
due to drugs and with a proper measure of cure of cancer, the probability of cure obtained will 
represent results from actual clinical trials. Description of various modules of the chemotherapic 




4.3.1. Incorporating the Effect of Drug into the Model (Pharmacodynamics, PD) 
Drug dosage is an important parameter in optimizing the drug treatment strategies for any 
disease. In a conventional sense, drug dosage denotes concentration or amount of the drug that is 
administered into the body. Generally, cell cycle phase specific chemotherapic drugs act by 
obstructing the natural progression of cancer cells through their cell cycle. Since the proposed 
reactions in the model are crucial for multiplication of cells through the processes of replication 
and division in cell cycle, inhibition of some of the reactions affects the growth of the cell 
population either by killing the cells or by delaying their progression through cell cycle. Thus, it 
is proposed here that a chemotherapic drug acts on the cells by inhibiting any of the biochemical 
reactions that are part of the cell cycle regulatory network. Inhibition of any reaction is carried 
out by reducing the values of the corresponding rate parameters by multiplying with a factor 
which named as inhibition factor. Extent of inhibition of targeted reaction varies with the 
concentration or amount of drug present in the body. Thus, in the present model, effect of a drug 
is incorporated by the degree of inhibition of the reaction that the drug targets. This is different 
from the generally followed PD relations to incorporate the effect of drug on the cancer cells, for 
example dose-response curves that relate dose to the killing effect of drug on the cells. Since, the 
model is in its primitive stages and there is not enough complexity in the model, any exact 
correlations between drug dosage and degree of inhibition are not introduced. So, comparison of 
two types of treatments for different drug dosages is done by comparing different degrees of 
inhibition of the target reaction. Furthermore, the term „dosage‟ is used frequently in place of 
„inhibition factor‟ in the later discussions.  
4.3.2. Types of Drug Administration (Drug Pharmacokinetics, PK) 




In the continuous administration, the degree of inhibition of a reaction is constant while the drug 
is being administered and falls to zero when the drug is no longer administered. This would be a 
simple model of e.g. a drug that is administered by a continuous drip or by a time formulation 
and removed quickly from the body once administration of the drug ceases. For simulations 
involving continuous administration, rate constant of the target reactions of the drug is multiplied 
by corresponding inhibition factors and their values kept constant from the time of drug 
administration till the end of the simulation.  
 A more complex scenario involves periodic administration of a drug which is modeled as 
periodic changes in the degree of inhibition of the target reaction, combined with removal of the 
drug from the body following administration.  After the drug administration, it can be removed 
from the body by being metabolized or by excretion (or by both). This type of time varying drug 
concentration is incorporated by different pharmacokinetic models that mainly use single or 
multiple compartment models as described in earlier sections. Here, a simple model is adopted 
where the first of the two mechanisms mentioned earlier will be modeled as a first order reaction, 
the latter as a zero order reaction. Doing so suggests that the degree of inhibition versus time can 
be modeled as an exponential decay or a linear decay. Hence, three cases of periodic 
administration are considered, viz. constant degree of inhibition (no decay of the drug during 
injection period), exponential decay and linear decay of the degree of inhibition of the drug. Fig. 
2 shows periodic administration characterized by the starting time of the drug injection, time gap 
between the two successive drug injections, effective time of the drug during which only drug 
shows its inhibitory effect and finally the degree of inhibition. During the exponential and linear 




start of the injection and upon which action of the drug is neglected till the start of the next 
periodic injection. 
 
Figure 2: Schematic of the periodic drug administration. 
4.3.3. Classification into Target Cells and Normal Cells 
 Cell population is classified into normal cells and target cells by selecting two separate 
sets of kinetic and growth parameters of the stochastic cell cycle model as shown in Tables 5 & 
6. Based on the type of cancer, cancer cells may divide at a faster or slower rate than the normal 
cells do. In the simulations of the present model, abnormal cells are assumed to be having higher 
growth rate than the normal cells which can be noticed from the values of the specific growth 
rate in the Tables 5 & 6. Monte Carlo simulation of the model for each set of parameters set will 
give the population growth dynamics for both types of cells the results of which are shown in the 
Fig. 3 and population average of some cell cycle properties for normal cells and target cells are 
shown in Table 4. Normal cells have almost equal durations of G1 and (S+G2+M) phases 
whereas the target cells have very small duration of (S+G2+M) phase compared to the G1 phase. 
The predicted difference in the properties of the two types of cells is due to the assumed 
difference in the specific growth rate and rate parameters for the mechanisms of cyclin synthesis 




Generally, cell cycle phase specific drugs exploit these differences in the cell cycle properties of 
normal and abnormal cells and a similar strategy is followed in the current model simulations. 
 In practice, inhibition by any particular drug of the reaction mechanism in the cell cycle 
network depends on the biochemistry of the drug and the genes involved in the mechanism. In 
the absence of information about biochemistry of the drug, equal inhibition effect is assumed for 
both types of cells for a given action of drug. In some compartmental models, researchers 
provide higher selectivity of the drug towards target cells by giving lesser value of cell kill rate 
for healthy cells than cancer cells. One such provision can be made in the present model by 
adjusting the cell death threshold value for the target cells. To selectively have higher action of 
the drug for target cells, the threshold value is reduced in some of the simulations. These are 
denoted as the target cells of type 2. There are oscillations that resemble qualitatively the cell 
cycle. There is antagonism between APC and cyclin levels. 
Table 4: Cell cycle properties for normal cells and target cells 










Normal cells 0.163552 0.297337 0.163545 1.473451 1.533916 3.007367 
Target cells  0.698833 1.443708 0.713909 1.558247 0.147951 1.699369 
target cells 
(type 2) 0.562545 1.116099 0.586075 1.624644 0.104821 1.725776 
 
Table 5: Parameters and Trigger values for slow growing populations 
          
           
          
           
       
         
         
         
               
Specific growth rate: 0.2 
Trigger Values 
Number of cyclin/Cdk molecules needed to trigger start: 40 
Number of cyclin/Cdk molecules needed to trigger division: 10 




Table 6: parameters and trigger values for fast growing populations 
         
           
          
           
       
         
         
         
               
Specific growth rate: 0.4 
Trigger Values 
Number of cyclin/Cdk molecules needed to trigger start: 40 
Number of cyclin/Cdk molecules needed to trigger division: 10 
Cell mass at which cell is considered dead: 2.5  
 
 
Figure 3: Monte Carlo solution of cell cycle model for normal and target cells 
4.3.4. Concept of Toxicity 
Toxicity of the drug towards normal cells limits the total dosage of the drug that can be 
administered in a given treatment period (also known as maximum tolerated dosage – MTD) and 
also limits the dosage of the drug at any instance during the treatment (known as dose limiting 
toxicity - DLT). Thus, toxicity is incorporated by simulating the effect of drug on healthy cells 
also. In the simulated results toxicity is measured in terms of surviving healthy cells fraction. If 
the effect of drug action results in reduction of healthy cell fraction more than the acceptable 
limits, then it cannot be a suitable drug treatment. This approach is very convenient to handle 
multiple toxicities. A single drug can lead to multiple toxicities, for example toxicities associated 




myalgias (Fetterly et al., 2008). If the model parameters are available for different types of cells 
related to these toxicities, it is easy to simulate the effect of the drug on those normal cells and 
thus to evaluate multiple toxicities in parallel to the tumor response and hence to control the 
scheduling and doses of drugs. In the simulation results, toxicity is discussed qualitatively in 
terms of the fraction of live healthy cells predicted during the treatment. 
4.3.5. Assumptions 
1. The model is assumed to be homogeneous in that all the cells are in a highly vascularized 
tissue and all these cells will be exposed to the same drug environment. Hence, during the 
drug effective period, the reaction parameters affected by the drug are modified with 
same value of inhibition factor for all the cells. 
2. The drug is assumed to be administered through intravenous injection and it is assumed 
to reach the tumor target site instantaneously.  
3. Evolution of drug resistance is not considered at this time.  
4. In case of multiple drug treatment, synergism between two drugs acting simultaneously is 
neglected and the drugs are assumed to have independent effect on cells. For including 
such interactions among the drugs, detailed biochemistry is needed which is not 
considered in this model.  
4.3.6. Reporting the Results of Drug Action Simulations 
Simulation results are reported in two different ways. One is the time course of total 
number of live cells in the population with or without the influence of drug. The simulations 
without the action of drug are referred to as WT (stands for Wild Type) case.  In some of the 
results, logarithm of the total number of live cells is used for convenience. Expressing the results 




Another convenient way is to express the results in terms of the time course of proportion of live 
cells compared to the WT type case, expressed as the ratio of the total number of live cells after 
any time period of a selected drug treatment strategy to the total number of live cells during the 
same time when there is no drug action (WT case). This ratio will give the survival fraction of 
the targeted cell population from the treatment if this treatment results in the reduction of the 
total number of live cells compared to the WT case.  
4.4. Results and Discussion 
Simulations are designed to demonstrate the usefulness of the model in identifying 
treatments that can simultaneously satisfy two important goals of chemotherapy viz. 
effectiveness in reducing the tumor size and keeping the toxicity to the normal cellular tissues in 
acceptable limits. First, set of reactions in the proposed cell cycle model are identified that can be 
used as potential drug targets for the selected cancer cell population. Second, for the drugs 
targeting the identified target reactions, various administration strategies are tested for a single 
drug by varying drug dosage, time interval between drug injections, and effective period of the 
drug. Finally, simulation results are presented for identifying combination of multiple drugs that 
are effective in satisfying both efficacy and toxicity requirements. 
Effect of treatment on curing the tumor is evaluated by determining the number of tumor 
(target) cells and the toxicity is determined by evaluating the number of normal cells after the 
treatment. The target reactions are identified in such a way that the treatment strategy satisfies 
both the requirements adequately. 
Simulation results of the time course of population growth of normal cells and target cells 




obtained to identify good target reactions. The results of the identification of the target reactions 
are presented in the Appendix B. 
Based on the results of the identification of target reactions, reactions 4 and 7 are 
identified as possible target reactions from the chosen cell cycle reaction network. The drugs that 
act on cells by targeting these reactions are denoted as drug 4 and drug 7 respectively. From the 
continuous inhibition simulations, the results for drug 7 show that, it is very effective for 
continuous inhibition, in selectively killing the target cells leaving the normal cells unaffected. It 
is effective even at small dosages and it has the tendency to increase the growth of the normal 
cells by speeding up their progression through cell cycle at low dosages. For Drug 4 to be 
effective in killing the target cells it should be applied at high dosage which will also severely 
affect the growth of normal cells.  
Prolonged continuous infusion, however, may facilitate the evolution of drug resistance 
by gradual processes such as gene amplification (Gardner and  Fernandes, 2003) and also causes 
severe toxicity problems and thus chemotherapic drugs are administered in periodic cycles. 
Cyclic treatment gives rest intervals for the normal cells to recover as well as for pulling 
quiescent cells to proliferating state. The disadvantage is that cancer cells start regrowth and the 
treatment duration increases. For that matter, the time gaps between the drug injections, time of 
drug exposure, and dose of the drug are important parameters in the treatment design 
considerations to achieve greater tumor control while limiting the toxicities. In the next section, 
the results of various periodic administration strategies involving drug 4 and drug 7 are presented 




4.4.1. Periodic Administration of Drug 4 
Same Gap - Dose Variation 
 For same gap and effective time, dosages (or degrees of inhibition of reaction 4) are 
varied and the effect on target cells and normal cells of this treatment is shown in Fig. 4. 
   
Figure 4: Periodic administration of drug 4 for various inhibition factors. Numeric notation (e.g. 
0.2,10,5,10) as shown in labels represent inhibition factor, time gap, effective time, drug 
injection time. 
 The total number of live cells is simulated for both types of cells for inhibition factors 
0.16, 0.2, 0.232 and 0.3. Simulations are done for effective time = 5 and time gap = 10 with the 
treatment started at time = 10. These simulations are similar to the dose escalating experiments 
generally conducted in the clinical trials for finding out the dose limiting toxicity (DLT).  
 From the Fig. 4, live cell fractions for the target cells decreases considerably with 
increasing dosage. The fraction drops to 0.05 after treatment time = 20 for 0.16 dose whereas it is 
equal to 0.2 for the dose 0.2. Increasing the dose has considerable advantage in killing the target 
cells as in the case of continuous inhibition. However, it is interesting to see if periodic 
administration helps normal cells to recover in the dug ineffective periods. From the Fig. 4, 
normal cell fraction fluctuates from 1 to 0.4 during the treatment time at high dosage of 0.16 and 
this fraction further reduces away from 1 as there are some cell deaths observed in these 




small with lesser dosage than the deviations observed for the dosage 0.16. Model predicts no cell 
deaths for normal cells for doses 0.2 and higher. The selected gaps at these doses are sufficient 
for normal cells to recover and hence their live cell fraction oscillates around 1. Based on the 
toxicity tolerance limits, we can either go for high dosage of 0.16 that has severe effect on 
normal cells or for a slightly lesser dosage of 0.2 that is not severe on normal cells. Through 
these results we demonstrate that the model predictions can be used to find out suitable dosages 
for a given periodic drug administration with known pharmacokinetics.  
Same Dose - Gap Variation 
 Time interval between the two drug infusions is another parameter that can be varied to 
improve the treatment effectiveness. From the earlier discussion, dose 0.16 was effective in 
controlling the target cell population, but it has caused large fluctuations in the normal cell 
populations at time gap between injections of10. Simulations are performed by varying the time 
interval between the drug infusions for values of  6,8,12 and 15 units and the response of the 
normal cells and target cells to the treatment is shown in the Figure 7 along with the response for 
gap = 10. Drug injection started at time = 10 and the effective time for drug is kept at 5. WT 
(wild type) represents the response of the cells when there is no action of drug.  
For same dosage, increasing the gap, its effect on the treatment efficacy is examined. At 
the selected dosage, all the target cells have died for gaps 6 and 8. Increasing the gap between the 
injections allows cancer cells to regrow and this is reflected in the results for higher gaps shown 
in Fig. 5. As the gap is increased to values of 10, 12, 15 increase in the target cell population is 
evident. However, there will be maximum tolerated toxicity (MTD) for any drug limiting the 
amount of drug that can be given in a single day. If such limitations exist on the periodic 




may not be possible. The effect of gap on the normal cell population is also shown in Fig. 5. 
Simulations predicted no deaths of normal cells for gap of value 6 and some deaths for all the 
higher gaps. As long as the gap does not result in any cell deaths, normal cells oscillate around 
the average value of around 0.8. This is better than the case of continuous inhibition at the same 
dose where live cell fraction for normal cells is maintained closed to 0.6 as in Fig. 5(b) of 
Appendix B without any cell deaths. As the gap is increased between the injections, some cell 
deaths have occurred resulting in a constant drifting away of the total live cell fraction from 
average value. Since periodic injection at dose 0.16 with small gaps is causing target cells to die 
and normal cells to have fewer oscillations around mean value, more frequent periodic 
administration of drug 4 is preferred to a less frequent administration with large gaps. Again, if 
there is a problem with the frequent application because of the portability of the drug injection 
equipment, these simulations help us to identify periodic administration strategy with the next 
best suitable gap.  
 
 




 For continuous administration for same dosage, all the target cells are dead as observed in 
simulations (not shown here), but normal cells have live cell fraction close to 0.6. By employing 
periodic drug administration, the impact on normal cells is reduced. The above results show that, 
keeping the frequency of drug administration high will keep the effectiveness of the treatment 
closer to that of continuous administration. 
Different Doses - Different Gaps 
 Sometimes, it is important to decide on how to distribute a total dosage in periodic 
administration. Weather to apply the drug in more frequent intervals with less dose each time or 
to apply the drug less frequently with large dose each time. Generally, AUC is used to find out 
the combinations of dose and frequency each giving rise to same total dosage over a total 
treatment time. Simulations are performed for various dose – frequency combinations to study 
their effect on cancer and normal cells. From the Figure 8(a), high dose (0.16) of drug 4 for less 
frequent injection is effective than small dose (0.232) with more frequent (continuous) injection. 
From Figure 6(b), more frequent injection at smaller dose (0.2) will be better than high dose 
(0.16) of drug at large gap between the injections for normal cells. Considering both toxicity and 
effectiveness of the drug 4, the intermediate dose 0.2 appears to be preferable to the other two 
doses (0.16 and 0.232). 
 From Fig. 4, dose of 0.2 is better than the dose of 0.16 from the toxicity point of view. 
For killing the target cells, 0.16 dose is preferred to 0.2 dose. Considerable improvement for 0.2 
dose is obtained by reducing the gap from 10 (Fig. 4) to 7 as in Fig. 6. More frequent injection at 
dose 0.2 has improved its effectiveness while keeping its toxicity to normal cells acceptable. 
Through this model, it is possible to find out suitable dose-frequency combinations that can 




(a) (b)  
Figure 6: Dose frequency combinations of administration of drug 4 
Effect of Drug Decay (Half Life)/Drug Pharmacokinetics 
All the previous results are presented for continuous inhibition without considering the 
pharmacokinetics of the drug in the body. Fig. 7 shows the results for administration of drug 4 in 
periodic pulses accompanied by exponential and linear drug decay instead of periodic 
administration with constant inhibition.  
  
Figure 7: Periodic administration of drug 4 with linear and exponential decay 
A dose of 0.16, gap of 10, effective time of 5 are considered and drug is administered at 
time = 10. For the selected effective time which indirectly signifies the half-life of the drug, this 
treatment has negligible effect on the target cell population for both types of drug decay. To have 
its effect, the drug should act for longer effective times in the body. In other words, half-life of 
the drug in the body should be very high. Fig. 8 shows the results for drug 4 with longer effective 
time of value 20, where there is not much effect on normal cells (Fig. 8(b)). There is not much 




some improvement with higher effective time (Fig. 8(a)). Thus, drug 4 may not be an effective 
choice when its pharmacokinetics is such that its action stays for less time in the body. These 
dependencies on pharmacokinetics suggest better formulations of this drug that will allow drug 
to stay for longer times in the body. 
(a)   (b)  
Figure 8: Periodic administration of drug 4 with linear and exponential decay with increased 
effective time of drug 
In the case of drug 4, the less effectiveness is due to the less retention time of the drug. If 
there was drug for more time, as in the case of uniform drug infusion, efficacy was more. So, the 
drug should be designed in such a way that there will be more retention time for the drug.  
4.4.2. Periodic Administration of Drug 7 
 In the case of drug 4, pharmacokinetics played an important role in the effectiveness of 
the drug in killing the cancer cells. Drug 4 was needed to stay for a long time in the body to show 
its effect on target cell population. Similar simulations to see the influence of pharmacokinetics 
on the effectiveness of the drug 7 in killing the target cells are performed at the dosage 0.6. 
Separate simulations are carried out for exponential, linear and no decay of the drug 7 with time 
gap = 10, effective time = 5 and injection starts at time = 7. The results of the simulations are 
shown in Fig. 9. Fraction of the live target cells predicted in the case of no decay of the drug is 




the cases of drug decay, unlike for drug 4, there is considerable decrease in the fraction of the 
target cells in the periodic treatment for drug 7. 
 
Figure 9: Efficacy of drug 7 with exponential and linear decay compared to no decay  
  
The amount of time drug stays in the body was enough to bring in a reduction in the size 
of the target cell population. In Fig. 10, fraction of cells with the exponential and linear decay for 
high dose of 0.3 is compared with the no decay case of drug 7 acting at low dose of 0.8. 
Increasing the dose of the drug has compensated for the lesser retention time due to the drug 
pharmacokinetic effects and the efficacy is more compared to the no decay case. Normal cells 
are not affected by this increase in the dose. These results demonstrate the differences in the 
effectiveness of the two drugs, drug 4 and drug 7 with different pharmacokinetic properties in 
killing cancer cells. 
 
 




 Dose - frequency simulations are performed for drug 7 as it is done for drug 4. For a drug 
effective time of 5 units, doses of 0.6, 0.75 and 0.8 are applied for 11 gap, 7 gap and continuous 
injection respectively. These values have been selected arbitrarily and the purpose is to 
demonstrate the use of the model for the case of drug 7 for various dose-frequency combinations. 
From the Fig. 11(a), 0.6 with gap 11 has high efficacy compared to the other high dose cases 
with frequent injection. However, the continuous injection of dose 0.8 is slightly better than the 
treatment with higher dose 0.75 with gap 7 between the injections. Since, the exact relationships 
are not defined for dose and the amount of inhibition it is not possible in the present model to 
choose the gaps and dose in a way to conserve the total amount of dose for a specific length of 
treatment period. As a consequence of this, the efficacies may vary for a different set of gaps for 
the chosen doses. For example, in the Fig. 11(b), simulation results for target cells of type 2 are 
presented for the same doses (0.6, 0.75, 0.8), but, with different set of gaps between the 
injections. From Fig. 11(b), frequent injection of drug 7 with dose 0.8 gives high efficacy than 
the other two cases which are more or less equally effective in killing the target cells. Combining 
such predictions from the model with the practical considerations like portability issues will 
result in best choice among a variety of dose-frequency combinations. 
 
(a) (b)  




Periodic Administration - Drugs Targeting Reactions 5 and 6 
 From the continuous inhibition simulations, it was seen that drugs targeting reactions 5 
and 6 are less effective in killing target cells at low doses but at higher doses those drugs affect 
normal cells also. Periodic administration strategies may ease the toxicity as is observed in the 
case of drug 4. Simulation results for the case of periodic administration of the drug 5 and drug 6 
are shown in the Fig. 12.  
 
(a) (b)  
(c)   
Figure 12: Effects of periodic administration of (a) drug 5 on target cells (b) drug 5 on normal 
cells and (c) drug 6 on both target and normal (shown as slow on the legend) cells. 
 
All the simulations are done by starting the drug injection at time = 10 and effective time 
= 5. At doses 0.7, 0.75, 0.725 the fraction of target cells does not drop much with the periodic 
treatment, but the efficacy of the drug improves if the dose is increased to 0.6. At the doses 
0.725, 0.75, fraction of the normal cells stays close to 0.8 during the drug effective time and the 
cells recover to the actual population size during the gap between the successive injections. As 




be observed by the gradually decreasing fraction of the normal cells with the treatment time. 
Similar result is obtained for periodic inhibition of the reaction 6 as shown in Fig. 12(c). At small 
dosages, there were not many target cells killed (results not shown here) and at the dose of 0.6, 
fraction of cells for normal cells is very less and the drug acts almost as severely on normal cells 
as it does on target cells. 
 These simulations suggest that treatment strategies by compounds that target reactions 5 
and 6 cannot be advisable from the considerations of their toxicity to normal cells. Hence, the 
present modeling approach based on the regulatory mechanisms controlling the division cycle of 
cell populations will give insights to the drug developers on what pathways to target and what 
pathways not to target for cell cycle based chemotherapy. 
Combined Action of Two Drugs 
 Conventionally, most of the chemotherapic drugs are administered in combination with 
other drugs to increase the effectiveness of the treatment. The present model is easily extended to 
include the action of multiple drugs. In the absence of detailed biochemistry of the drugs, it will 
be difficult to include any interactions among the drugs which can affect the overall inhibition 
effect by the combined action of the drugs. Hence, it is assumed that the inhibitory effect of any 
drug on a particular reaction is independent of the action of any other drug on the same reaction. 
Simulations are performed for the case of continuous inhibition, to demonstrate the combined 
effect of two drugs targeting different reactions. Corresponding rate constants are multiplied by 
inhibition factors to represent each drug action. Fig. 13 shows the examples of drug 
combinations for continuous drug administration where both drugs act synergistically in 
improving the efficacy of the treatment by killing more number of target cells than their 




population. In Fig. 13(b), drugs 4 and 7 are combined with doses 0.3 and 0.85 respectively. In 
Fig. 13(a), drug 6 and 7 are combined with doses 0.8 and 0.85 respectively. In both the cases, 
live cell fraction of normal cells stayed close to 1, whereas the combined effect of treatment on 
target cells is highly significant.  
(a)  (b)    
Figure 13: (a) Combined effect of drug 6 and drug 7 on target cells and normal cells; (b) 
Combined effect of drug 4 and drug 7 on target cells and normal cells. 
 A different scenario where the combined action of drugs does not show significant 
improvement in the treatment is shown in Fig. 14. In Fig. 14(a), Drug 5 and Drug 4 are combined 
with doses 0.75 and 0.3 respectively and this combination does not succeed in reducing the target 
cell population even though the live cell fraction of normal cells stays close to 1. For the 
combination of drugs and doses shown in Fig. 14(b), (drug 5 and Drug 6 are combined with 
doses 0.8 and 0.8 respectively), both normal cells and target cells are affected severely and thus 
this combination cannot be used for a successful treatment. 
(a)   (b)  
Figure 14: (a) Combined effect of drug 5 and drug 4 on target cells and normal cells; (b) 




4.4.3. Summary of the Results  
Continuous inhibition of each reaction in the cell cycle network is simulated to identify 
target reactions. Drug 4, Drug 7 which indirectly contribute for keeping active APC at higher 
levels by inhibiting reactions 4, 7 respectively in the cell cycle network are identified as suitable 
for controlling the selected tumor type. Such predictions about target reactions for drugs will be 
helpful in development of new drugs targeting those pathways. These simulations are not only 
helpful in identifying target reactions, but also helpful in finding out the limits on the dosage of 
drugs. These are similar to the dose escalation studies performed in clinical trials. However, 
continuous inhibition simulations also reveal the effect of cell cycle specific drugs on normal 
cells which is a measure of toxicity and suggest periodic drug administration. Periodic 
administration allows cells to recover in the gaps between successive drug injections. Using drug 
4 and drug 7, periodic drug administration strategies are tested by varying drug dose, gap 
between the injections, different dose – gap combinations and by including drug 
pharmacokinetics for both drugs 4 and drug 7. The results for suitability of other drugs reveal 
their ineffectiveness even when periodic administration is considered. Same model is used to 
find the combination of drugs that can work in synergy to cure tumor without affecting normal 
tissues. Continuous inhibition simulations are performed on both cancer and normal cells for 
synergistic action of drug combinations. 
4.3. Conclusions 
A chemotherapic model is developed based on stochastic chemical kinetics of cell cycle 
regulatory network and Monte Carlo simulations are used to compute the time course of the 
growth of cancerous and healthy cell populations in response to chemotherapic treatment. Effect 




the cell cycle progression. This approach helps in predicting the action of multiple drugs on 
tumor cell growth. Toxicity is considered by simulating the inhibitory effect of drug on healthy 
cell population growth. By including the effect of the drug action on the growth of both healthy 
and cancer cells, the model demonstrates the pathway to determine favorable treatment strategies 
for varying dosages, drug effective times and time gaps between drug injections. A simple linear 
or exponential decay of the drug is included in the drug testing simulations. 
Model‟s predictability is helpful and useful in clinical trials to identify administration 
strategies that are best suited to each individual. If the parameters are obtained from the patient 
specific biopsies, tailoring treatments to each individual is possible. If the parameter space is 
available that represents a population of random patients, this model can predict the result of 
drug treatment for each such combination of parameters which averaged on the whole population 
gives probability of cure for a specific drug during the drug development stage. Hence, in silico 
screening of drugs is possible with the present modeling approach. 
Compared to many deterministic models available in the literature, the present stochastic 
formulation has the benefits of dealing with intra-patient variability. – Tumors are associated 
with variability among cell population and each of them will respond independently to 
chemotherapic drugs which is an important factor when cell cycle phase specific drugs are used.  
Cell cycle specific drug action is easily handled in the current modeling formulation as 
the model is based on the progression of the cells through cell cycle. However, cell cycle non-
specific drug action also can be easily implemented. Cell cycle non-specific drugs target genes 
(for example p53) that act outside the cell cycle, which are involved in DNA damage, apoptosis 
pathways. By simply adding another module that includes these reaction networks, it is easily 




mechanisms in the stochastic chemical kinetics formulation. This is similar to the integrated 
approach described in Ribeiro & Pinto (2009) except that they followed deterministic approach.  
 The present modeling approach is very useful as it follows an integrated methodology in 
which multiple modules can be added independently. In the present study, a simple cell cycle 
model representing a model eukaryotic organism is used. A more detailed and more realistic 
reaction network can be used in future work. Similarly, it is easy to use different drug 
pharmacokinetics in place of simple linear and exponential decay. Single and multiple 
compartmental models are generally used to represent various barriers for representing drug 
transport from the drug intake till it acts on its gene target on the cellular and subcellular region. 
Similar provisions are possible for modifying drug pharmacodynamics by incorporating well 
defined correlations between the dose and degree of inhibition of the target reaction such as 
Emax, sigmoidal relationships. Another important module in the integrated model is the genetic 
resistance to the acting chemotherapic drugs. It is not considered in the present model in its 
preliminary stage. It can be incorporated as another module. Gene amplification, random 
mutations to the genes involved in drug metabolism and alternate metabolic pathways are 
identified as some of the possible mechanisms for evolution of drug resistance. These genetic 
interactions and reaction pathways can be combined with the cell cycle network as another 
module for describing drug resistance. The effect of drug on cells manifests in terms of the 
reduced inhibition factor of the selected drug on its target reaction.  
 With the current approach it is possible to evaluate toxicity and tumor control 
independently which is useful considering the fact that each patient will have different objectives 
and concerns (i.e., cure or palliation) related to the treatment. Also, there are many types of 




cells that may affect the treatment (Gardner and  Fernandes, 2003). These toxicities can be 
handled by using parameters specific to the corresponding normal tissues, in the tumor growth 
model. Using this methodology, we do not have to resort to simultaneous optimization of toxicity 
and tumor cell kill as described in optimal control models of (Swierniak et al., 2003) where only 
one type of toxicity is considered. 
Through the present model, simultaneous action of multiple drugs can be tested by 
making changes to inhibition factors of their respective target reactions in the cell cycle reaction 
network. One way to obtain the exact relationship between drug dose and resulting inhibition 
factor is by combining drug kinetics with the cell cycle network as is done by Chappel et al. 
(2008) using a deterministic formulation. Any interactions among the drugs acting 
simultaneously is not considered at the moment, as it demands more biochemical details and 




CHAPTER 5. SELECTION OF MODEL PARAMETERS 
5.1. Introduction 
5.1.1. Background and Motivation 
Parameter estimation for stochastic models needs a special consideration. One way of 
finding the stochastic model parameters is by using the rate parameters obtained from 
deterministic models. Deterministic models are fit to experimental data by classical least squares 
optimization tools to obtain the rate parameters and these can be converted to the equivalent rate 
parameters for stochastic kinetics. However, such conversions are not always possible, especially 
when the rate expressions are not in the form of simple mass action kinetics. Another issue is that 
stochastic kinetic models of a given reaction network will have more model parameters than the 
deterministic model of the same network. All the reaction propensities must be determined to 
complete the model. One possibility to determine these parameters is by fitting the model to 
transient distribution of reactant molecules which can be used to estimate the parameters of the 
stochastic model. Since there will be large number of species involved in most of the 
biochemical networks, real time measurements of molecular concentrations for large enough 
number of cells is needed to calculate the required transient distribution. Obtaining such a huge 
amount of real time data is not always an easy task.  
An alternative strategy is to fit the model to steady state distributions of states of cell 
population that can be easily obtained from flow cytometry measurements. Obtaining the 
property distributions for cell population from Monte Carlo simulation of the present stochastic 
cell cycle model is described earlier. The distributions obtained from the model will depend on 
the values of the reaction propensities and other model parameters. Thus, biologically reasonable 




obtained experimentally using the usual least squares techniques. This is a well-known technique 
applied for DNA distributions (Dean and  Jett, 1974; Johnston D. A., 1978; Bailey, 1981). Fitting 
the distributions to models with large number of parameters is a challenging problem as it may 
result in over fitting. Thus, a wise strategy is to seek the solution of least squares problem in 
terms of only those parameters that have considerable impact on the distributions. In the present 
work, a method is developed that will be helpful in identifying the importance of different 
parameters on the observed distributional properties and also helpful in obtaining a good starting 
guess of the parameters for the least squares problem. 
Budding yeast Saccharomyces Cerevisiae is considered as model organism for eukaryotic 
cell cycle studies and the characteristics of its cell population distributions are widely 
understood. The gene regulation and biochemical pathways related to cell cycle progression of 
yeasts are similar to those found in higher eukaryotes. Thus, logical step to handle the parameter 
selection problem for stochastic models is to start with the distributions of budding yeast cell 
populations and then to extend the understanding to higher organisms.  
5.1.2. Objective 
The main objective of the current chapter is to present a methodology to refine the basic 
cell cycle model described earlier such that the population characteristics derived from the model 
resemble the characteristics of budding yeast cell populations and to implement a parameter 
selection algorithm that selects values of the parameters that optimize a specific characteristic of 
the population derived from the model. Specifically an evolutionary optimization strategy, 
termed here as insilico evolution is proposed that selects the stochastic model parameters 




The idea of selecting parameters that optimize a particular property of distributions is 
developed similar to the idea of flux balance analysis (FBA) that has been widely used in 
metabolic pathway analysis (Schilling et al., 2000; Orth et al., 2010). The objective of FBA is to 
select the optimal distribution of metabolic fluxes of each reaction in the network to maximize a 
phenotype or production of a particular metabolite. There might be many combinations of the 
individual reactions that give optimal solution. The range of values of contribution from a 
specific reaction gives the sensitivity of the objective function to changes in fluxes from that 
reaction, which is determined by flux variability analysis. In the present work, insilico evolution 
is employed as the optimization strategy to select the combination of parameters contributing to a 
maximize population growth rate. Maximum population growth rate of cells can be easily 
obtained from the cells growing in exponential phase.  
Insilico evolution is initially applied to the basic cell cycle model to gain insights into the 
salient features of the proposed methodology. The stochastic cell cycle model is then 
reformulated to include more realistic features of budding yeast cell population. To make the 
model more realistic, model parameters with arbitrary units are assigned proper units of mass 
and time based on the comparison of properties of distributions obtained from the model with 
those collected from the literature data. At this stage, the model with its realistic parameters is in 
a more refined form than the basic model. The insilico evolution is then applied on the refined 
model to improve the values of model parameters corresponding to cells with maximum growth 
rate.  
5.2. Parameter Selection by Insilico Evolution 
The insilico evolution method which is described in the next section requires initial set of 




systematic approach to tune the stochastic cell cycle model parameters to cause oscillations, 
characteristic of cell cycle dynamics, is discussed by Sherpa and Hjortso (unpublished work) and 
the parameter set used in the basic cell cycle model is obtained from the same approach which is 
briefly explained here. First, reactions that are not essential for onset of oscillations are turned 
off. Even though a rigorous mathematical analysis is possible using center manifold analysis, this 
process can be carried out by inspection for simple reaction networks. The rate constants for the 
still active reactions are then determined by turning off all reactions except those determine the 
dynamics in the early part of the cell cycle. Reaction parameter values are adjusted by hand until 
one obtains a response that is in qualitative and, to the extent possible, quantitative agreement 
with experimental observations. Reactions that determine the dynamics of next sequence of 
events in the cell cycle oscillator are then turned on and their associated parameters adjusted by 
hand as before. This continues until all reactions are activated at which point the model oscillates 
and the parameter set is ready to be used in the insilico evolution algorithm. 
5.2.1. Insilico Evolution Algorithm 
The final parameters obtained from the insilico evolution will result in cell cycle 
oscillations and represent the cells with maximum population growth rate. The description of the 
algorithm is as follows. 
The basic idea of the insilico evolution is built on the process of natural evolution. 
Initially, there will be a specified number of cells in the system all having the same set of 
parameters of the cell cycle model. 
The parameters of the model which affect the propensities of various cell cycle pathways 
are perturbed randomly (characteristic of mutation) at each cell division and each of the newly 




on the new set of model parameters. The extent of perturbation (or mutation) of the existing 
value of any parameter depends on the mutation rate which is assumed to take values between 0 
and 2, where a value of 0 corresponds to no mutation and a value of 2 corresponds to maximum 
range of possible mutated values which is double the magnitude of the parameter value. The 
perturbation of the parameter is related to the mutation rate by the following expression which is 
schematically represented in the Fig. 15.   
                                                         
Where,        represents the parameter after division and         represents the parameter 
before division occurred. The „random number‟ is a real number uniformly distributed in the 
interval [0,1].  
 After the population increases to a pre-specified size, some cells will be 
eliminated from the system to bring the population back to the original size and the process of 
mutation and elimination of the cells is repeated. After many repetitions of the procedure, cells 
that have a low population growth rate and maximum likelihood of death will be eliminated and 
the existing cells in the system will have a high population growth rate. The set of parameters 
corresponding to the existing cells are selected as the improved parameters compared to the 
initial parameter set that gave oscillations. 
 
 





5.2.2. Linking Perturbations in Parameters to the Change in Population Growth Rate 
During Insilico Evolution 
 Perturbations to the parameters of the cell cycle model influence the cell cycle 
progression. By knowing the relationship between cell cycle progression and the single cell 
specific growth rate, it is possible to relate the perturbations in the parameters and the resulting 
effect on the population growth rate. For zero order single cell growth kinetics, specific growth 
rate of cell continuously changes during the cell cycle from maximum at the start to minimum at 
the end. Based on this fact, a population with smallest average cell mass will have highest 
population growth rate. Hence, by assuming zero order growth kinetics of single cell, parameters 
corresponding to the lowest possible cell mass in the evolution can be selected as those giving a 
population of maximum growth rate.  
5.2.3 Insilico Evolution Simulations 
In the present work, all the simulations of insilico evolution are started with 100 new 
born cells and 10 cells are selected randomly and eliminated from the system once the total cell 
population reaches a number of 110 cells. These simulations are performed till 10000 iterations 
whenever possible to resemble the natural evolution in which new traits occur due to mutations 
over many generations. 
Evaluation of the Algorithm 
To evaluate the algorithm, it is tested with an initial condition of an equal number of fast 
growing and slow growing cells and a zero mutation rate. For this system, the algorithm should 
select for the faster growing cells and eventually eliminate the slower growing population 
completely. These cells are classified as slow growing and fast growing cells based on the 




(Parameter k4 in this case) are assigned to these cells growing in zero order kinetics. The cell 
cycle properties of these two types of cells are listed in Table 7. The differences in the values of 
cell mass after and before cell division highlight that fast growing cells divide at lower cell mass 
than the slow growing cells which is expected when zero order single cell growth kinetics are 
used.  
Table 7: Fast and slow growing cells 
Average values Fast Cells Slow Cells 
mass at birth 0.403929 0.497314 
mass just before division 0.807758 0.99277 
G1 duration 2.01007 2.462842 
G2 duration 0.009074 0.01444 
Doubling time 2.019144 2.477282 
Reaction parameter, k4  400 85 
 
The results of insilico evolution are shown in Fig. 16 in terms of number of fast cells and 
slow cells in the system which started with 50 cells of each type. When 10 cells are randomly 
eliminated from the system, only fast growing cells remain after 146 iterations eliminating all the 
slow cells. These results give confidence in the effectiveness of the insilico evolution algorithm 
in selecting cells with maximum growth rate. 
 





5.2.4. Application of the Insilico Evolution for the Basic Cell Cycle Model 
Insilico Evolution Results for a Single Mutation Rate 
The insilico evolution algorithm is then applied to the basic cell cycle model to get 
insights into the parameter selection problem which can be used to the refined budding yeast cell 
cycle model discussed later. Simulations are carried out for different mutation rates. Results of 
average values of the parameters and cell mass for the 100 cells remaining after each iteration of 
the insilico evolution for a mutation rate of 0.4 are shown in Fig. 17. 
For this mutation rate, convergence in mass was reached rapidly around 2000 iterations. 
All the rate parameters, after initial transient, will continue fluctuating even after the cell mass 
has converged. These fluctuations are very high for some parameters and are small or moderate 
for some parameters and some parameters remain constant with negligible fluctuations. These 
fluctuations in the parameters can be seen as different combinations that give same optimal 
solution as is done using flux balance analysis (FBA) of metabolic networks. From the Fig. 16, 
parameter k1 reaches a very high value compared to the initial value it was started with. 
Parameters k1 and k4 change up to magnitude of 10 times, whereas parameter k5
‟‟
 changes up to 
several orders of magnitude. The parameter Nx converges to a constant value of 2 and remains 
constant. The insilico evolution simulations qualitatively perform sensitivity analysis of the 
model parameters. The parameters that fluctuate to large extent will have less effect on the 
population distribution than those parameters that fluctuate by small amount. However, the 
magnitudes of these fluctuations are very high for the parameters shown in Fig. 17. It is not 
convincing to think that they are different combinations of parameters giving the same optimal 
solution. It happens when the rate at which mutations to the parameters are occurring is very 




rate. Simulations results from two different mutation rates are compared to gain some insights 




Figure 17: Insilico evolution simulation results for Zero order kinetics, mutation rate 0.4, The 
starting values for the parameters are, k1 = 800; k4 = 280, k5” = 200.  
Influence of Mutation Rate in Insilco Evolution 
Simulations are performed for different mutation rates ranging from very small to high 




Results for some mutation rates of 0.4 and 1.2 are presented in Fig. 18. It appears that the 
convergence has reached at around 2000 iterations for mutation rate of 0.4 and it has not yet 
reached for the rate of 1.2 even after 5000 iterations. There is still some transient in the average 
mass curve for mutation rate of 1.2. The value of parameter k1 when the cell mass is close to the 




Figure 18: Effect of mutation rate on convergence to the final solution. 
 After reaching the convergence for the rate 0.4, further perturbations to the parameter k1 
did not cause any improvement in the value of optimum cell mass. Hence, the selection process 
is not in pace with the mutation process. For the case of high mutation rate of 1.2, even for large 
fluctuations, there is still some transient in the cell mass. The selection process is still responding 
to the large changes in the parameter values suggesting that there should be a definite 




simple terms as the ratio of maximum specific growth of an individual in the population to the 
average specific growth of all the cells.  
The concept of mutation and selection in the present case can be explained as followed. 
There are two rates of changes in the system, one is the rate of change of parameter values and 
another is the rate of change in the population composition in terms of specific growth rate of 
each cell. The rate of change of parameter values can be viewed as characteristic rate of mutation 
and the rate of change of population composition can be viewed as characteristic rate of 
selection.  
If the characteristic rate of mutation is significantly higher than the characteristic rate of 
selection, then the selection process cannot keep up and there is chance of best traits being lost in 
the evolution. This should result in traits that are not the best possible. In the current optimization 
problem, the best trait we are looking for is the maximum population growth rate which is 
reflected in minimum average cell mass of the cells in the system, and if we compare the values 
of the converged mass for low mutation rate and high mutation rate, the above point is reflected. 
Average cell mass for low mutation rates is less compared to that for high mutation rate and this 
difference increases with the difference in the mutation rates. 
Only if the mutation rate is slow enough does the selection process have a chance to have 
an effect and only then do we see meaningful results. If the characteristic rate of mutation is too 
high, there is danger of extinction of the species in the evolution. Similar results are reflected in 
the present scenario of parameter selection through evolution. For the simulations started with 
high mutation rates, the initial perturbations in parameters caused lot of cell deaths and the 




mutation rate and selection rate so that mutation rate can be adjusted in the evolution process to 
match the selection rate. 
5.3. Refining the Basic Cell Cycle Model  
5.3.1 Model Description 
With the insilico evolution algorithm working properly, the next logical step is to start 
with realistic parameters that lead to population characteristics that are close to the 
experimentally observed values. A literature survey on yeast models and experiments to identify 
properties characteristic of the yeast cells is done (Hartwell, 1974; Hjortso and  Bailey, 1982; 
Barberis et al., 2007; Di Talia et al., 2007; Barik et al., 2010; Bryan et al., 2010). Many 
observations are made in the literature regarding the cell division of budding yeast and some of 
which are mentioned below. A schematic of the cell division model based on these observations 
is shown in Fig. 19.  
 
 





M: cell cycle time of mother cell 
D: cell cycle time of daughter 
m0: mass of daughter cell immediately after cell division 
m
*
: critical mass (cell mass required for start event to occur) 
md: cell mass at the time of division 
 Mother cells will divide into a new cell of mass close to a constant value known as 
critical cell mass and the daughter cell will obtain a mass less than critical cell mass.  
 The mother cell cycle time is roughly constant, independent of growth conditions, while 
the daughter cell cycle time varies strongly withy growth rate, being shorter at higher 
growth rates and longer at lower growth rates.  
 The start event which is considered as the checkpoint for starting the DNA synthesis, will 
not occur until the critical cell mass is reached.  
The stochastic model is modified to incorporate these changes. The modifications are as 
followed.  
 The “start event” will not occur until cell grows to the critical mass in addition to the 
condition of the earlier model in which start event occurs only after cyclin/Cdk molecules 
reach a threshold value. 
 Cell will not divide until it attains a mass that is at least equal to the sum of critical cell 
mass and minimum required cell mass. Earlier condition is for the cell to attain a mass 
that is double the minimum mass. 
 At the time of division, partition of the total cell mass occurs in such a way that mother 





 Daughter cell will not synthesize any cyclins until it reaches the size of the critical cell 
mass. This provision is to prevent multiple oscillations during the cell cycle of daughter 
cell before the threshold value of mass for division is reached as shown in the Fig. 20. 
 
Figure 20: An erroneous behavior of multiple oscillations of daughter cell in cell cycle 
5.3.2 Evaluation of the Refined Model 
The qualitative behavior one should observe with this kind of model is that the mass 
distribution obtained for the cell population should give a curve with double peak with the 
distribution shifting towards lower cell mass at lower growth rates and moving to higher cell 
masses at high growth rates with almost unimodal distribution. The results depicting the same 
behavior are as shown in Fig. 21. Here, parameter „nu‟ is the specific growth rate of single cell 
that is used in the cell cycle model simulations with first order kinetics. 
At very low specific growth rates, a large fraction of the population consists of cells of 
small cell mass and as the specific growth rate is increased, distribution shifted towards higher 
cell mass. The second peak in the above distribution occurs at the exact value equal to 0.88, 
which is the critical cell mass chosen, at all the specific growth rates. In practice, this peak will 
not occur at a fixed value for all the growth rates, instead it shifts towards right as the growth rate 
is increased. To include such realistic behavior, value of the mother cell mass is not taken exactly 






Figure 21: Mass distribution for various specific growth rates; at the time of division, mother cell 
attains a mass equal to critical cell mass and the daughter cell gets the remaining mass. 
A simple 4
th
 order algebraic equation is used to get the distribution of mother cell mass at 
the time of division which is given by the following equation. 
     
            
 
 
Where,   = lower bound for cell mass =                
  = upper bound for cell mass =                
  = Maximum allowed deviation of new cell mass from the value of 
critical mass 
     
 
 = critical cell mass 
  = area of the curve              in the interval       






Figure 22: Mass distribution for various specific growth rates, mother cell divides exactly 
according to a probability distribution centered on critical cell mass  
Apparently, the peak on the right side of the distribution shifts towards higher cell mass 
rather than staying at the critical cell mass, as the specific growth rate is increased which is 
reasonable with the realistic budding yeast cell mass distributions.  
For higher specific growth rates, it is observed in the simulations that daughter cells will 
attain larger mass than the mother cell at the time of division which is not reasonable. Thus, the 
specific growth rate should be limited to some value above which it is not feasible to have a 
biologically reasonable distribution.  
5.3.3. Assigning Units to the Parameters 
Another step towards making the model more realistic is to assign reasonable parameters 




that the simulation results match the experimental data is to compare specific properties of the 
distribution obtained both from experiments as well as from the model simulations and to use 
this comparison as to estimate the values of the model parameters. The two properties of the 
distribution that are used for obtaining units to the initially dimensionless parameters are average 
cell cycle time of mother cell and the critical cell mass of the cell population. It is proposed and 
experimentally verified in an earlier study that cell cycle times of mother cells are almost 
constant at the time of division, whereas variability exists among the cycle times of daughter 
cells (Hartwell and  Unger, 1977).  
Value of average cell cycle time of mother cells is calculated for dimensionless 
parameters and equated to the experimentally observed values to obtain the conversion factor for 
arbitrary time units to minutes. Similarly, the critical cell mass of mother cells is equated to the 
average cell mass of the distribution of cell masses to obtain the conversion factor for cell mass. 
Values of critical cell mass and the constant mother cell generation time are taken from 
the experimental data of (Hartwell and  Unger, 1977).  
Average volume of the newly born mother cell at the time of division = 79.4±15.2 µm
3
. 





Density of yeast is taken as 10% more than that of water 
Density of yeast cell = 1.1 g/cc 
Average mass of a mother cell at the time of division = 80×10
-12
 cc × 1.1 g/cc = 0.88 pg 
(pico gram) 






Simulations are carried out for the parameters used in the basic cell cycle model. The 
properties of the distribution for the arbitrary units (AU) using first order kinetics and zero order 
kinetics are given below. 
First order kinetics 
Average cell mass from the distribution = 0.35 mass AU 
Mother cell generation time (or cell cycle time) = 1.65031 time AU 
Specific growth rate,   = 0.2 time-1 
Conversion factors: 
 0.35 AU = 0.88 pg (pico gram) 
 1.65031AU = 135 min 
Zero order kinetics 
Average cell mass from the distribution = 0.324417 mass AU 
Mother cell generation time (or cell cycle time) = 1.62 time AU 




 0.324417 AU = 0.88 pg (pico gram)  
 1.62 AU = 135 min 
Resulting parameters for both the kinetics are shown in Tables 8 & 9. 
Table 8: Parameters and growth rate for zero order kinetics 
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Table 9: Parameters and specific growth rate for first order kinetics 
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5.4. Insilico Evolution Simulations for the Modified Model with Units  
Insilico evolution algorithm is now applied for the updated model of the basic cell cycle 
model. All the cell cycle parameters are given units as shown in the conversion calculations 
earlier. The parameters used in the simulations are as shown in Table 9. Simulations are carried 
out for different mutation rates varying from low 0.2 to high range 1.0 and the results are 
presented below and discussed. 
5.4.1 Results and Discussion 
Average mass of cells in the system stays constant after sufficiently large number of 
iterations of insilico evolution for different mutation rates. Fig. 23 shows the convergence of 
mass for two mutation rates, one is a low rate 0.2 and another is a higher rate 0.4. Convergence 
reached quickly (around 2000 iterations) for low rate compared to the higher rate (around 3000 
iterations). The idea behind the insilico evolution is based on the linking of growth rate to the 
cell mass using zero order growth kinetics. For zero order kinetics, the smaller the mass of the 
cell, the higher is its specific growth rate. Thus, when the convergence in mass is achieved 
during the insilico evolution, the cells in the system have reached maximum possible growth 
rate. In the later discussion, the term “convergence” used frequently to refer to the condition of 
maximum population growth rate and not to any other parameters. The characteristics of the 
population in terms of cell cycle time and population growth rate determined from the cycle time 




of the refined model using the model parameters found out from the insilico evolution for the 
case of two mutation rates, at the time of convergence. The parameters used are shown in Table 
9. The calculated population characteristics are in reasonable agreement with the values observed 
for the yeast strains used in our research lab.  
 
 
Figure 23: convergence of cell mass for mutation rates 0.2 (Left) and 0.4 (Right) 
 
Table 10: Parameter values at the time of convergence for mutation rates, 0.4 and 0.2 
Mutation Rate 0.2 0.4 
Convergence considered after 
Iteration - 2000 3000 
k1 8.136948 61.91434 
c2 3.92E-05 8.61E-05 
k3 0.018778 0.250774 
k4 1.305939 3.538061 
J4 0.010195 0.014855 
k5_1 0.366755 0.143234 
k5_11 4.601016 405.8477 
J5 1.511774 0.182309 
k6_1 0.01643 0.000514 
k6_11 23.40614 60.04024 
J6 139.1396 10.92971 
Nx 5.041864 2.016789 














0.4 98.666 0.007025 
0.2 97.6 0.0071 
 
For both the mutation rates, similar trends are observed for the evolution of parameters of 
cells in the system. Plots showing the variation of parameters in the insilico evolution for 
mutation rate 0.2 are shown in Fig. 24, Fig. 25 and those for mutation rate 0.4 are shown in Fig. 
26, Fig. 27. One typical behavior observed is that those parameters either increase or decrease 
towards improved values as the cell mass approaches its convergence and then they start 
fluctuating, remain constant or follow the same direction of increase or decrease with 
intermittent fluctuations. Fig. 24 shows the results for parameters – k1, k3, k4, k5”, c7 and k6” 
for a mutation rate of 0.2. For example, parameter k5” smoothly reaches a value close to 5 at the 
time of convergence, and then fluctuates rarely falling below this value. It fluctuates by a factor 
of 7 to reach 35. The range of these fluctuations indicates the sensitiveness of the parameter k5” 
in the model. Parameter c7 also follows a similar behavior of reaching a value of 0.15 at the time 
of convergence and then fluctuates around this value with a maximum factor of 2. Fluctuations 
are observed in parameters k1, k3, k4 and k6”. However, the magnitude of deviations of the 
values of these parameters from the values observed at convergence varies. It depends on the 
sensitivity of the model to each parameter.  
Fig. 25 shows some parameters which do not show many fluctuations. They either move 
towards a final value asymptotically or stay constant. Parameter Nx remains constant at the 
starting value of 5 with minor fluctuations. Parameters c2, k5‟ and k6‟ approach values close to 












Figure 24: Parameters in insilico evolution for mutation rate, 0.2. There are small fluctuations in 
these parameters till the point of convergence, fluctuations of different magnitude are observed 














Figure 25: Parameters of the insilico evolution for mutation rate, 0.2. Parameter Nx, fluctuates 




The insilico evolution results for mutation rate 0.4 are shown in Fig. 26, Fig. 27. 
Parameter k1 reaches a value close to 50 at the time of convergence, and then fluctuates rarely 
falling below this value of 50. It changes by a factor of 7 to reach 350. Parameter k3 also follows 
a similar behavior of reaching a value of 0.1 at the time of convergence and then starts 
fluctuating up to a factor of 7. Parameter k5” also reaches a value at the time of convergence and 
undergoes fluctuations of several orders of magnitude in line with the fluctuations observed for 
parameters k1 and k3. Similar trend is observed for parameter c7.  
Results for parameters J6, Nx, k6”, c2, J5 are shown in Fig. 27. Parameter J6 reached 
convergence in the case of high mutation rate of 0.4 whereas it fluctuated for low mutation rate 
of 0.2. Nx remains constant for the case of high mutation rate also, however, it attains a different 
constant value of 2 compared to a value of 5 observed for low mutation rate. Similarly, 
parameter k4 does have fluctuations of small magnitude despite large fluctuations in parameters 
k1, k3, c7, k5”. Parameters like J6, Nx, k4 whose values stay in a close range in the insilico 
evolution seem to be important for the parameter estimation problem because their possible 
values for a given growth rate are in small range. Thus, insilico evolution algorithm gives an idea 
about the sensitivity of the model to different parameters. 
Effect of mutation rate 
Many nonlinear optimization search algorithms, when they are far away from optimal 
solution use large magnitudes of perturbations in the optimization variables and the perturbations 
become small when near the optimum. It is a point of investigation to see how mutation rate 
which is an indication of perturbation made to the parameters, changes with the distance from the 
optimal solution. It is mentioned in the earlier discussion about the parameters that show 












Figure 26: Parameters in insilico evolution for mutation rate,0.4. Parameter k5” fluctuates to 
several orders of magnitude, while k1, k3, c7 fluctuate to a factor of 7. Model appears sensitive 












Figure 27: Insilico evolution of parameters for mutation rate, 0.4. Parameters J6, Nx reached 
convergence. The other parameters stay close to zero due to large fluctuations in parameters k5”, 




system have reached their maximum possible growth rates), will not show much fluctuations 
before reaching the convergence. They moved in a smooth manner towards the optimal solution 
where cells grow at a maximum rate, only then started fluctuating to considerable magnitude 
without causing any cell deaths. At low growth conditions, where the parameters are far away 
from the optimal solution, the perturbations in the parameters should be very small. Hence, for 
the present initial parameters, it appears that we should start with small mutation rate. The results 
of the insilico evolution simulations performed for large mutation rates confirm this point. All 
the cells have died after a few iterations of the insilico evolution for very high mutation rates. 
After reaching the optimal solution, the magnitude of fluctuations is large for higher 
mutation rates than for small mutation rate. For example, parameter k5” fluctuates to several 
orders of magnitude for mutation rate of 0.4 compared to fluctuations in other parameters k1, k3, 
c7 which change by a factor of 7. This shows that the parameter k5” may not be that important in 
fitting the model to steady state distributions using least square technique. However, for the 
mutation rate of 0.2, the magnitude of fluctuations of k5” is comparable to the fluctuations in the 
values of parameters k1, k3, c7. This makes it equally important in the model fitting even though 
it is shown to be less important from the high mutation rate observation. Thus, using higher 
mutation rates after reaching the optimal solution helps in identifying sensitivity of parameters. 
The time to reach convergence and also execution time of the algorithm may change with 
mutation rate. The algorithm is executed for mutation rate of 0.6 and the result of convergence of 
cell mass is shown in Fig. 28. It has reached the lowest value of cell mass, which is the optimum, 
in less than 2000 iterations, but do not appear to be converged as it continues fluctuating. Also, 
the average cell mass for the population is slightly higher than that observed for lower mutation 




Table 5. It took less time for the execution of algorithm to 10000 iterations for low rate of 0.2. 
Even though the execution time for the rate 0.6 is less than that for the rate 0.4, the doubling time 
of cells is high which gives a less population growth. Thus, mutation rate is an important factor 
to be investigated to accomplish many improvements to the insilico evolution algorithm 
proposed here, when applied for more complex models. 
 
Figure 28: Convergence of cell mass for mutation rate of 0.6 
Table 12: Execution time and average cell mass for different mutation rates 
Mutation Rate 0.2 0.4 0.6 
Total Execution Time, min 65 248 208 
Average time for iteration, 
milli sec 396 1490 1247 
Doubling time, min 83.5 87.13 97.1 
Average mass, pg 0.856 0.9168 1.04 
5.4.2 Summary 
Using insilico evolution algorithm, optimal parameters are obtained that gave the 
population doubling time in reasonable agreement with the experimental value. These parameters 
can be selected as an initial estimate of the model parameters. Cell mass converges towards a 
minimum value and parameters either tend towards a lower value or higher value at the point of 




small to large range in the parameters are observed. The extent of fluctuations gives an idea 
about the sensitivity of the model to these parameters when the selection rate is keeping up with 
the mutation rate. If the mutation rate is fast enough that there is no improvement in the 
population composition, then all the perturbations in the parameters are random variations and 
we cannot draw many conclusions from that without investigating further on mutation rate. 
Large fluctuations of the parameters mean that the parameter will have less influence on the 
dynamics of the population. Mutation rates affect the speed of achieving the solution and these 
are to be intelligently adjusted to get to the final solution minimizing the fluctuations.  
5.5. Conclusions 
The basic cell cycle model is modified to include the features observed for experiments 
of budding yeast. Mother cells are assumed to acquire a constant cell mass known as critical cell 
mass and daughter cells will have large variations in their mass at the time of birth. Simulations 
are performed by including the feature of critical cell mass in the cell cycle model and the shape 
of mass distributions obtained for specific growth rates of large range give reasonable result. 
Further direction from the insilico evolution simulations is to use a least square fit of 
distributions of states of key components of cell cycle oscillator those are obtained from flow 
cytometry.  There are least square techniques available in the literature to fit DNA distributions 
to the models (Dean and  Jett, 1974; Johnston D. A., 1978; Bailey, 1981). However, even a 
moderately realistic cell cycle model will have many parameters some of which may not be 
having great impact on the goodness of the fit of the distributions. The parameters of importance 
for the fitting problem can be identified from the insilico evolution simulations by the range over 
which they fluctuate. In addition to the insilico evolution simulations which give an idea about 










CHAPTER 6. CONCLUSIONS AND FUTURE DIRECTIONS 
A stochastic model developed based on a cell cycle model that is representative of a 
simple eukaryotic system is described. The kinetics of biochemical interactions among the 
species involved in the chosen cell cycle network are described by stochastic formulation and 
stochastic simulation algorithm is used to simulate the time course trajectories of the state of the 
system. Using a Monte Carlo strategy, a large number of independent simulations of the system 
with the same initial state will give different realizations of the state and thus give a distribution 
of states. All the cells in the same initial state will attain different states in time and thus the 
model depicts the loss of cell synchrony and the population heterogeneity in terms of their states 
is predicted from the stochastic model based on single cell kinetics. Thus, the stochastic cell 
cycle model presents Monte Carlo solution to the population balance equations.  
Model‟s ability to predict the population growth and to represent the heterogeneity of 
population is used in developing an integrated chemotherapic model that combines the growth of 
cells described by cell cycle model with simple pharmacokinetics describing the decay of drug in 
the body and pharmacodynamics describing the killing effect. Killing effect of a cancer drug on 
healthy cells and cancer cells will be different and selection of a type of drug injection in terms 
of various dose-frequency combinations to maximize the killing on cancer cells and minimizing 
the effect on healthy cells are tested using the basic cell cycle model with different parameters 
for each type of cells. Such a methodology has great scope in predicting the outcome of a drug 
treatment and drug administration protocol on a heterogeneous patient population and thus to 
assist in insilico screening of cancer drugs and testing clinical trial protocols.  
Budding yeast is a model organism frequently studied for cell cycle research and the 




the budding yeast. The mass distributions predicted from the model are in qualitative agreement 
with the experimental observations. At high growth conditions, the mass distribution contains a 
double peak and it becomes unimodal at very low growth conditions which is predicted by the 
model. The qualitative agreement is not sufficient to use it in making predictions about the 
behavior of organism and thus a systematic methodology is developed in a direction to make the 
model accurate in quantitative aspects as well. Plausible values of the model parameters with 
proper units are assigned by making comparisons between the average mass and doubling time 
of the population of cells with the predictions obtained from model parameters with arbitrary 
units. Insilico evolution, an optimization strategy, is used to predicting the evolution of model 
parameters through generations of mutation and selection towards the parameter values that 
correspond to maximum growth rate of the population. There are many combinations of the 
model parameters that are selected by the evolution algorithms as to give maximum growth rate. 
Insilico evolution simulations show fluctuations to several orders of magnitude for some 
parameters, fluctuations in a close range for some indicating different sensitivities of the model 
parameters. The exact set of parameters can be obtained by using nonlinear least squares 
techniques to fit the distribution of important proteins in the biochemical network obtained from 
the model to the measured distributions. Insilico evolution, however, serves to identify the 
important parameters in terms of goodness of fit to the distributions, which only can be used for 
model fitting problem. From the computational aspects, further investigation of effect of 
mutation rate on improving the speed of selection, optimal solution. 
A methodology presented for budding yeast with small set of compounds and reactions 
can be extended to more complex networks containing large number of reactions. Presently, 




model for a simple eukaryotic system of biochemical network to more realistic networks of 
budding yeast cell cycle containing 10 components and 42 components respectively. The 
challenges lie ahead in handling more diverse set of reaction kinetics concepts such as quasi 
steady state assumption, partial equilibrium, and stiffness in the reaction set for which 
implementation of approximation algorithms is to be investigated. The original exact stochastic 
simulation algorithm (SSA) of Gillespie (1976, 1992) will perform satisfactorily for small 
systems and will be computationally demanding when it has to deal with large set of reactions as 
discussed in a study (Kierzek, 2002). Approximate algorithms discussed in the chapter 2 of this 
report are developed to speed up the simulations. Combining these approximations with parallel 
computing power of clusters of computers and multiprocessors should make the computational 
requirements less demanding and this is another direction for future work. Another task is to 
improve the features of insilico evolution strategy. At present, a single mutation rate is used to 
obtain the optimum solution starting from an initial set of parameters. Based on the discussion in 
the previous chapter, mutation rate might influence the speed of convergence of the optimization 
problem and also it may lead to different optimal solutions.  
Developing stochastic models with more realistic features and combining them with the 
advanced computing technologies will help us in realizing many applications of those models in 
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APPENDIX A. DOCUMENTATION FOR THE INSILICO EVOLUTION PROGRAM IN 
VB.NET 
A.1. Overview  
Insilico evolution is a type of evolutionary optimization method that we employed for 
selecting the best parameter set for the stochastic cell cycle model, that give maximum 
population growth rate of cells. Like other optimization search algorithms, the execution of 
algorithm requires an initial guess of the optimization variables. Here, the optimization variables 
are the parameters of the cell cycle model. The working principle of the algorithm and the cell 
cycle model on which the insilico evolution program is built is described in chapter 5 of this 
report. Here, the procedure for the execution of the user interface developed in VB.Net platform 
is explained for convenience of the users of this program. 
Various windows in the user interface are explained below. 
A.2. Main Window 
 
Figure A1: Main Window for Insilico Evolution code 
As is shown in the window, it asks for the seed to start the random number generator in 
the program. Entering a negative number, the program will generate the seed according to the 
timer in the system. User can give any value for the seed. Clicking on the “Exit” tab, terminates 




A.3. Model Parameters 
 
Figure A2: Opening window after clicking on “Model Parameters” tab.  
Clicking on the “Model Parameters”, the main window will like above. There are five 
different sub menus appear. 
A.4. Model Parameters - Cell Cycle Reactions 
Clicking on the “Cell Cycle Reactions” will open a new window as shown below. 
 
Figure A3: Opening window after clicking on “Cell Cycle Reactions” in “Model Parameters” tab 
of main window. 
 
The window is self-explanatory. These are the initial cell cycle parameters for all the 




“Save Parameters” clicking on which the program asks for the file name to load or save the 
model parameters respectively. 
Clicking on “Done” will close the window. 
A.5. Model Parameters – Trigger Values 
Clicking on the “Trigger Values” will open a new window as shown below. 
 
Figure A4: Opening window after clicking on “Trigger Values” in “Model Parameters” tab of 
main window. 
As written on the window, it asks for entering the trigger values for the start, division and 
cell death events. 
Clicking on “Done” will close the window. 
A.6. Model Parameters – Division 






Figure A5: Opening window after clicking on “Division” in “Model Parameters” tab of main 
window. 
 Minimum Cell Mass is the minimum biologically possible value of cell mass for 
budding yeast. 
   is the maximum deviation allowed from the value of critical cell mass that is assigned 
to the mother cell after division. 
 Constant Mother Mass is the value of the critical cell mass. In the model, start event 
occurs only when cell mass crosses this threshold.  
Clicking on “Done” will close the window. 
A.7. Model Parameters – Single Cell Growth 
Clicking on the “Single Cell Growth” will open a new window as shown below. 
 Clicking on the button “First Order Single Cell Kinetics” will ask for specific growth 
rate, with units as time
-1
 
 Clicking on the button “Zero Order Single Cell Kinetics” will ask for growth rate for zero 





Figure A6: Opening window after clicking on “Single Cell Growth” in “Model Parameters” tab 
of main window. 
Clicking on “Done” will close the window. 
A.8. Model Parameters – Mutation Rates 
Clicking on the “Mutation Rates” will open a new window as shown below. 
 
Figure A7: Opening window after clicking on “Mutation Rates” in “Model Parameters” tab of 
main window. 
 Mutation Range is the range by which the model parameter can be perturbed from the 
existing value. Mutation range should have a mean value equal to one.  
Clicking on the “Mutation Rates” will open a new window as shown below. 
A.9. Main Window – Enter Seed Value for Random Number Generator 
After completing all the inputs in the Model Parameter, click on “Done” in the main 





Figure A8: The Main Window, shown again to proceed further after completing the inputs. 
After entering the “seed” value for the random number generator, click on “Done” and 
the main window appears as shown below. 
A.10. Main Window – Enter Inoculum Size 
 
Figure A9: Opening window when clicked on “Done” after entering the “seed” value. 
 User should enter “Inoculum Size” which by default uses a value of 100 in the algorithm. 
This is the number of cells to start with in the insilico evolution algorithm. 




A.11. Main Window – Load Inoculum File 
 
Figure A10: Main Window after clicking on “Enter Inoculum Size”. 
After entering the size of the inoculum, user needs to select the file from which the initial 
cells should be selected.  This file is called inoculum file in our model terminology.  
 Inoculum File – This is the file where states of a large set of new born cells are stored. 
State of the cell is in terms of the mass, and number of molecules of each of the four 
components and the status of the cell in terms of start event occurred or not. Since all 
these cells are newly born, the „start event‟ is stored as FALSE, a Boolean variable. 
A.12. Main Window – Save Parameter Values after Each Iteration 
 




After supplying the program with the „inoculum file‟ and clicking OK, a new window 
opens as shown above. It will ask for the user if the parameters after each iteration of the insilico 
evolution simulations should be saved. 
These parameters are the average of each of the parameters for the 100 cells in the system 
after eliminating some of the cells randomly.  
If clicked „yes‟, user need to specify the file name in which the parameters will be stored 
and proceeds to the next step. 
If clicked „no‟, the program proceeds to next step. 
A.13. Main Window – Save Final Distribution 
User will be asked then if the final distribution of states should be saved. The window is 
as shown below. 
 
Figure A12: New Window opens after clicking on „yes‟ or „no‟ to the save parameters window.  
 Final Distribution of States – This is the distribution of the states of the 100 cells 
existing in the system after each iteration. By default, program stores the states of five of 




A.14. Main Window – Start 
After responding „yes‟ or „no‟ for saving the final distribution, the Main Window will 
look like this. 
 
Figure A13: Main Window after clicking „yes‟ or „no‟ on the save final distribution window. 
At this stage, all the inputs to the program are given and the program is ready to start 
executing. 
Clicking on the “Start” button, Main Window appears as shown below. 
 
Figure A14: Main Window while the program is being executed. 
The value in the box for “Iteration No” is the number of iterations of insilico evolution 
program execution that have been completed.  
A.15. Data Files 
The results of the insilico evolution simulation are stored in two files. One is the file for 
storing the average model parameters, cell mass and doubling time of the cells existing after each 
iteration and execution time of the iteration. It also contains the input values supplied to the 





Figure A15: Output file in which parameters at the end of each iteration are shown 
Another output file is for saving the final states of a selected number of cells after each 
iteration. This will be helpful if we need to check how the states of the cells change as the 





Figure A16: Output file for saving the final distribution of states of cells existing in the system 







APPENDIX B. IDENTIFICATION OF TARGET REACTIONS FOR CHEMOTHERAPY 
MODEL 
B.1. Identifying the Target Reactions for Chemotherapic Drug 
Simulation results of the time course of population growth of normal cells and target cells 
for continuous inhibition of each of the seven reactions for wide ranging inhibition factors are 
obtained to identify good target reactions. In Figure B1, natural logarithm of number of live cells 
(Nc) is plotted with time for the two cyclin degradation reactions (reactions 2, 3). The population 
of the target cells has increased as a result of inhibition and thus these two reactions are 
eliminated as the target reactions for drug.  
(a)  (b)  
Figure B1: inhibitory effect of reaction 2 (a) and reaction 3 (b) on target cell population growth 
The corresponding results for the other reactions are shown in Figure B2 expressed in 
terms of the time course of the fraction of total live cells in normal and target populations at 
different inhibition levels (denoted by different inhibition factors). An ideal drug target reaction 
should have the value of the live cell fraction approaching zero for target cells and one for the 
normal cells after inhibition. However, from Figure B2(a), it appears that both types of cells are 
equally affected by inhibiting the cyclin synthesis reaction (reaction 1). For low inhibition 
factors, only a small reduction in the fraction of target cells is obtained and at higher inhibition 
more number of cells are killed and the fraction moves close to zero. But, the same trend is 




cell fraction of healthy cells is less than that of the target cells.. For example, at 0.333 dosage (k1 
= 500 slow) healthy cells fraction is close to 0.6, whereas at 0.31 dosage, fraction of the target 
population is close to 0.6 (between doses 0.31 and 0.35). Hence, the inhibition effect is acting 
almost equally on normal and target cells which reveals that targeting reaction 1 is suitable for 
reducing tumor burden but not recommended from the toxicity considerations Periodic injection 
of the drug that facilitates the normal cells to recover from the slow growth because of the 
inhibition may help the treatment to be effective. On the basis of continuous inhibition, reaction 
1 may not be suitable target for the present target cells. 
 APC inactivation (Reaction 4) (Figure B2(b)) appears to be a target reaction for a 
chemotherapic drug. For normal population, at 0.2 dosage (k1 = 160), the fraction is close to 0.7 
and will increase for higher doses. At nearly the same dosage (0.232), the fraction of target cells 
is very less.  
(a)        
Figure B2: inhibitory effect of reactions 1,4,5,6,7 (a,b,c,d,e  respectively) on population growth 
of target cells (left side) and normal cells (right side). In the labels in figures, fast denotes target 








(Figure B2 continued) 
(b)     
(c)        
(d)     
(e)          
For continuous inhibition the inhibition factor (or dosage) can be varied between 0.2 – 
0.325 without causing toxicity to the normal cells. For this dosage range, live cell fraction of the 




are identical to the dose escalation studies conducted in clinical trials to establish safe dose limits 
for chemotherapic drug administration strategies 
APC activation (reaction 5) (Figure B2(c)) is not a target reaction as it appears as 
equivalently toxic to both target cells and normal cells. At 0.725 dosage, the toxicity of the drug 
targeting reaction 5 is more dominant than its effectiveness in killing the target cells. A similar 
observation can be made for reaction 6 (activator protein synthesis) (Figure B2(d)). Hence, both 
these reactions fail to be good targets when acted alone on body of cells containing both normal 
and target cells.  
Reaction 7 (activator protein degradation) (Figure B2(e)) is a possible target reaction. At 
the dosage 0.25, the fraction of healthy cells is around 0.8. For higher doses, this fraction is 
slightly above 1 which is an indication of reduced cell cycle length of normal cells. For target 
cells, for 0.75 dosage, the target cell fraction is very less and if the dosage is increased up to 0.5, 
almost all the cells will die. The large negative slope of the time course plot of target cells while 
the slope for normal cells is close to zero indicates that continuous action of the drug at specific 
dosages will contribute to the high rate of killing of target cells without affecting normal cells. 
Since the fraction of healthy cells is close to 0.8 even at 0.25 dosage, the range of drug dosage 
for continuous inhibition of reaction 7 can be selected as 0.25 – 0.8 (for this dosage, live cell 





APPENDIX C. FORTY THREE COMPONENT MODEL 
C.1. Description of the Model and Molecular Mechanism 
Stochastic cell cycle model is developed based on the deterministic model presented in 
(Chen et al., 2004). A brief description of the molecular mechanism proposed in the 
deterministic version is described here. A single cyclin-dependent kinase (Cdk), cdc28 
combining with two families of cyclins, Cln1-3 and Clb1-6 controls the major cell cycle events 
in the budding yeast. It is approximated that cdc28 is present abundantly and rapidly combines 
with cyclins as soon as they are synthesized. Cln1-2 play major role in bud formation and their 
concentration peaks in late G1 phase. Cln3 governs the size of the cell and the initiation of Start 
event (license to start DNA synthesis). Clb5-6 are responsible for initiating DNA replication 
whereas Clb3-4 assist in the replication process. At least one of Clb1-Clb2 pair is necessary for 
completing mitosis. In the model some of these cyclins are lumped together and represented as a 
single cyclin. Cln2 represents Cln1-2, Clb2 represents Clb1-2, Clb5 represents Clb4-5. Clb3-4 
are not included in the model as they are considered to be assisting the activities of other cyclins.  
Most of the earlier part of the G1 phase is abundant in proteins (Cdh1, Sic1 and Cdc6) 
whose role is to keep S/G2/M phase cyclins, Clb5 and Clb2 in low concentrations. Cdh1/APC 
degrades the cyclins whereas Sic1 and Cdc6 together referred to as cyclin-dependent kinase 
inhibitors (CKIs), inhibit the activity of cyclins. Cell grows to a critical size in G1 phase to have 
enough Cln3 and Bck2 that activate the transcription factors SBF and MBF for synthesizing Cln2 
and Clb5. Cln2 and Cln3 are not inhibited by Cdh1 and CKI activities. When the abundance of 
Cln2 reaches sufficient level, it inhibits the activities of Cdh1 and CKIs leading to the synthesis 
of Clb5. Clb5 and Cln2 together shut off the activities of CKI and Cdh1 and this will allow the 




after Clb5 and Clb2 are reached to sufficient levels. After the cell enters S-phase, synthesis 
activities of Cln2, Cln3 and Clb5 are turned off and Clb2 drives the cell into mitosis. Clb2 
phosphorylates the components of anaphase promoting complex (APC) and stimulates the 
synthesis of Cdc20 which is crucial for the cell‟s exit from mitosis in combination with mitotic 
exit network (MEN) pathway.  
MEN pathway contains proteins Lte1, Bub2, Tem1, Cdc15 and Cdc14 with the ultimate 
result of releasing Cdc14 in active form from RENT complex. Cdc14 is required for the exit of 
mitosis. Cdc14 plays role in the activation of CKIs, Cdh1 and inactivation of Cdks. Cdc15 is the 
end point of the MEN pathway and is responsible for the release of Cdc14. Cdc15 is activated by 
Tem1. Bub2 is a checkpoint protein which prevents the exit from mitosis if there are defects in 
the mitotic spindle pole formation. Lte1 is involved in the activation of Tem1. 
APC/cdc20 becomes active when Mad2-dependent checkpoint signal is released after the 
chromosomes are aligned properly and it initiates the exit from mitosis. First, it degrades Pds1 
releasing Esp1 prompting the sister chromatid separation. Active Cdc20 promotes degradation of 
phosphatase PPX that keeps Net1 in its active unphosphorylated form which holds on to Cdc14 
forming RENT complex. When PPX is degraded, Net1 gets phosphorylated by Cdc15 releasing 
Cdc14 which acts against Cdks in the activation of Cdh1 (degrades cyclin Clb1-2) and Swi5 
(transcription factor for Cdk-inhibitor Sic1) and returns the cell to G1 phase.  
C.2. List of Biochemical Reactions Representing the Cell Cycle Network 
The set of biochemical reactions and corresponding reaction propensities and reactant 




Table B3. These are derived from the deterministic model of (Chen et al., 2004). However, 
modifications are made in the formulation of some of the reactions and reaction propensities. 
Production of both Cln3 and Bck2 are taken as continuous variables and proportional to 
the cell mass in the deterministic model.  
       
      
        
;              
In the stochastic formulation, these expressions are included as reaction propensities for 
synthesis reactions of Cln3 and Bck2 respectively. 
Table B1: some differences in the reaction kinetic expressions between the deterministic and 
stochastic versions of the budding yeast cell cycle model 
No. Reaction Reaction Propensity No. of reactant 
combinations 
3. Cln3 synthesis   
       
   
      
        
 
1 
4. Bck2 synthesis   
              1 
 Cdh1, Net1, Swi5, is synthesized in active form, but degraded in both active and inactive 
forms. 
 Cdc14 is synthesized in active form and degraded in inactive form. 
 Cdc20 is synthesized in inactive form. 
 The rate expressions for activating [SBF], [MBF],[Mcm1] contain Goldbeter functions 
that act as switches in the deterministic model. Mechaeli‟s Menten formulae are used in 





Table B2: List of Reactions used in the stochastic model 






1. Cln2 degradation   
               [Cln2] 
2. Cln2 synthesis   
               
      
         1 
3. Cln3 synthesis   
       
   
      
        
 
1 
4. Bck2 synthesis   
              1 
5. Clb5 synthesis   
                
       
          1 
6. Clb5 degradation   
               
       
           [Clb5] 
7. Inhibition of Clb5 by Sic1   
                        [Sic1][Clb5] 
8. Inhibition of Clb5 by Cdc6   
                        [Cdc6][Clb5] 
9. Clb2 synthesis   
                
       
           1 
10. Clb2 degradation   
                
       
         
      
            
[Clb2] 
11. Inhibition of Clb2 by Sic1   
                         [Clb2][Sic1] 
12. Inhibition of Clb2 by Cdc6   
                         [Clb2][cdc6] 
13. Activation of promoting factor SBF   
                   
      
             
             
              
              
          
[SBF]i 
14. Inactivation of promoting factor SBF   
               
                 
      
        
        
             
 
[SBF]a 




                     
           
             
 
[Mcm1]i 
16. Inactivation of promoting factor 
Mcm1 
  
                     
     
             
 
[Mcm1]a 
17. Swi5 synthesis   
                    
        
          1 
18. Degradation of active Swi5   
                     [Swi5]a 
19. Inactivation of CKI promoting factor 
Swi5 
  
                                  [Swi5]a 
20. Degradation of inactive Swi5   
                     [Swi5]i 
21. Activation of CKI promoting factor 
Swi5 
  
                                    [Swi5]i 
22. Sic1 synthesis   
                
       
          1 
23. Cdc6 synthesis   
                
       
          1 
24. Phosphorylation of Sic1   
            
                            
           
       
    
       
      
              
             
  1, 2   2+  1, 2   2+  1, 5  
 5+  1, 2   2  
[Sic1] 
25. Dephosphorylation of Sic1P   
                               [Sic1P] 
26. Degradation of Phosporylated Sic1   
                   [Sic1P] 
27. Dissociation of inactive trimer C2 to 
Clb2, Sic1 
  
                         [C2] 
28. Degradation of Clb2 in inactive 
trimer C2 
  
                 [C2] 
29. Phosphorylation of Sic1 in trimer C2   
                [C2] 
30. Dephosphorylation of Sic1P in trimer 
C2P 
  
                [C2P] 




                  [C2P] 
32. Clb2 degradation in trimer C2P   
                   [C2P] 
33. Dissociation of inactive trimer C5 to 
Clb5, Sic1 
  
                         [C5] 
34. Degradation of Clb5 in inactive 
trimer C5 
  
                [C5] 
35. Phosphorylation of Sic1 in trimer C5   
                [C5] 
36. Dephosphorylation of Sic1P in trimer 
C5P 
  
                [C5P] 
37. Degradation of Sic1P in trimer C5P   
                  [C5P] 
38. Clb5 degradation in trimer C5P   
                  [C5P] 
39. Phosphorylation of Cdc6   
            
                       
          
             
    
       
     
             
             
  6, 2   2+  6, 2   2+  6, 5 
  5+  6, 2   2  
[Cdc6] 
40. Dephosphorylation of Cdc6P   
                               [Cdc6P] 
41. Degradation of Phosporylated Cdc6   
                   [Cdc6P] 
42. Dissociation of inactive trimer F2 to 
Clb2, Cdc6 
  
                         [F2] 
43. Degradation of Clb2 in inactive 
trimer F2 
  
                 [F2] 
44. Phosphorylation of Cdc6 in trimer F2   
                [F2] 
45. Dephosphorylation of Cdc6P in 
trimer F2P 
  
                [F2P] 
46. Degradation of Cdc6P in trimer F2P   
                  [F2P] 
47. Clb2 degradation in trimer F2P   




48. Dissociation of inactive trimer F5 to 
Clb5, Cdc6 
  
                         [F5] 
49. Degradation of Clb5 in inactive 
trimer F5 
  
                [F5] 
50. Phosphorylation of Cdc6 in trimer F5   
                [F5] 
51. Dephosphorylation of Cdc6P in 
trimer F5P 
  
                [F5P] 
52. Degradation of Cdc6P in trimer F5P   
                  [F5P] 
53. Clb5 degradation in trimer F5P   
                  [F5P] 
54. Inactivation of hypothetical protein 
IE (may be the phosphorylated form 
of APC) 
  
                   
      
             
 
[IEP]a 
55. Activation of hypothetical protein IE   
                   
            
             
 
[IEP]i 
56. Synthesis of Cdc20 (in inactive form)   
                    
       
          1 
57. Degradation of inactive-Cdc20   
                     [Cdc20]i 
58. Activation of Cdc20   
                            
       
         [Cdc20]i 
59. Inactivation of Cdc20   
                             [Cdc20]a 
60. Degradation of active-Cdc20   
                   [Cdc20]a 
61. Synthesis of Cdh1 (in active form)   
                     1 
62. Degradation of active-Cdh1   
                     [Cdh1]a 




                    
 
 
              
       
 
       
               
                           
                 
 
[Cdh1]a 
64. Activation of Cdh1   
                 
    
      
        
          
              
 
[Cdh1]i 
65. Degradation of inactive-Cdh1   
                  [Cdh1]i 
66. Inactivation of Tem1   
                     
     
              
 
[Tem1]a 
67. Activation of Tem1   
                     
     
              
 
[Tem1]i 
68. Activation of Cdc15   
                            
        
      
         
      
            
[Cdc15]i 
69. Inactivation of Cdc15   
                             [Cdc15]a 
70. Synthesis of Cdc14 (in active form)   
                     1 
71. Degradation of active-Cdc14   
                     [Cdc14]a 
72. Formation of RENT complex   
                                 [Net1][Cdc14]
a 
73. Formation of RENTP complex   
                                    [Net1P][Cdc14
]a 
74. Net1 synthesis   
                 1 
75. Net1 degradation   
                 [Net1] 




               
        
        
             
[Net1] 
77. Dephosphorylation of Net1P   
                      
        
        [Net1P] 
78. Degradation of Net1P   
                [Net1P] 
79. Degradation of Net1 in RENT 
complex 
  
                       [RENT] 
80. Degradation of Net1P in RENTP 
complex 
  
                        [RENTP] 
81. Dissociation of RENT complex   
                                 [RENT] 
82. Dissociation of RENTP complex   
                                    [RENTP] 
83. Degradation of Cdc14 in RENT 
complex 
  
                     [RENT] 
84. Degradation of Cdc14 in RENTP 
complex 
  
             
                        
        [RENTP] 
85. Dephosphorylation of Net1P in 
RENTP complex 
  
                    [RENTP] 
86. phosphorylation of Net1 in RENT 
complex 
  
            
                      
       
         
        [RENT] 
87. PPX synthesis   
                 1 
88. PPX degradation   
         
       
 
 
      
                        
           
 
[PPX] 
89. Pds1 synthesis   
                 
        
        
       
           
1 





                          [Pds1][Esp1] 
91. Dissociation of PE to Pds1 and Esp1   
                          [PE] 
92. Degradation of Pds1 in PE   
                   
        
          
       
           
[PE] 
93. Pds1 degradation   
       
                    
        [Pds1] 
Table B3: List of variables in the model 
Variable Symbol Species 
N(1) Cln2 Cyclin involved in budding 
N(2) Cln3 Cyclin initiating start event 
N(3) Bck2 Protein initiating start event 
N(4) Clb5 Cyclin appearing in the late G1, involved in the synthesis of DNA 
N(5) Sic1 Stoichiometric inhibitor of Clb2, Clb5 
N(6) C5 Trimer of Clb5/Cdk and Sic1 
N(7) Cdc6 Stoichiometric inhibitor of Clb2, Clb5 
N(8) F5 Trimer of Clb5/Cdk and Cdc6 
N(9) Clb2 Cyclin essential for exit from mitosis, present in S/G2/M phase 
N(10) C2 Trimer of Clb2/Cdk and Sic1 
N(11) F2 Trimer of Clb2/Cdk and Cdc6 
N(12) (SBF)i Transcription factor for Cln2, in inactive form 
N(13) (SBF)a Transcription factor for Cln2, in active form 
N(14) (Mcm1)i Transcription factor for Clb2, Cdc20, Swi5 in inactive form 
N(15) (Mcm1)a Transcription factor for Clb2, Cdc20, Swi5 in active form 
N(16) (Swi5)a Transcription factor for Sic1 and Cdc6, in active form 
N(17) (Swi5)i Transcription factor for Sic1 and Cdc6, in inactive form 
N(18) Sic1P Phosphorylated form of Sic1 
N(19) C2P Trimer of Clb2/Cdk and Sic1P 
N(20) C5P Trimer of Clb5/Cdk and Sic1P 
N(21) Cdc6P Phosphorylated form of Cdc6 
N(22) F2P Trimer of Clb2/Cdk and Cdc6P 
N(23) F5P Trimer of Clb5/Cdk and Cdc6P 
N(24) (IEP)i Intermediary enzyme, a hypothetical protein involved in activating 
Cdc20, in inactive form 
N(25) (IEP)a Intermediary enzyme, a hypothetical protein involved in activating 
Cdc20, in active form 
N(26) (Cdc20)a Activator of the APC; protein involved in Clb2, Clb5 and Pds1 
proteolysis, and required for exit from mitosis, in active form 
N(27) (Cdc20)i Inactive form of Cdc20 





N(29) (Cdh1)i Inactive form of Cdh1 
N(30) (Tem1)a Protein activating Cdc15 in MEN pathway, in active form 
N(31) (Tem1)i Inactive form of Tem1 
N(32) (Cdc15)a Component of MEN pathway, essential for releasing Cdc14, in 
active form 
N(33) (Cdc15)i Inactive form of Cdc15 
N(34) (Cdc14)a Phosphatase required for exit from mitosis, exists in active form 
N(35) Net1 Stoichiometric inhibitor of Cdc14 
N(36) Net1P Phosphorylated form of Net1 
N(37) RENT Complex formed from Net1 and Cdc14 
N(38) RENTP Complex formed from Net1P and Cdc14 
N(39) PPX Phosphatase keeping Net1 in unphosphorylated form that binds to 
Cdc14 
N(40) Pds1 Stoichiometric inhibitor of Esp1 that prevents sister chromatid 
separation 
N(41) Esp1 Protein required for sister chromatid separation 
N(42) PE Complex formed from binding of Pds1 to Esp1 
N(43) Cell Mass Continuous variable, mass of cell 
The current model is described by 93 reactions consisting of 121 parameters, 43 state 
variables including cell mass, as shown in Tables B2 &B3. Cell progresses through various 
phases of cell cycle as the trigger values are satisfied.  
For the cell to progress through the cell cycle, following events should occur in the order. 
Each event is described with the corresponding trigger variable in the parenthesis. 
1. Origin re-licensing (when Clb2+Clb5 drops below threshold) – cell will be ready for next 
round of replication 
2. Origin activation (when Clb2+Clb5 subsequently raises above threshold) – DNA 
synthesis  will start 
3. Entry into mitosis when spindle is aligned (when Clb2 rises above threshold) 
4. Esp1 activation (when Esp1 rises above threshold, after Pds1 is degraded) – cell is ready 




5. Nuclear division (when Clb2 drops below a threshold) – cell division occurs 
Another condition that is included in the model is the provision for cell death occurrence. 
When the cell mass increases above a threshold value, cell is considered dead. 
C.3. Modules for the VB code 
 



















Figure C4: Visual Basic form for supplying the Parameters for reactions 
C.4. Approach for the Selection of Initial Conditions and Trigger Events 
 For the model to be executed, initial conditions and trigger values should be selected 
properly along with the parameter values to give oscillations. Ghaemmaghami et al. 
(Ghaemmaghami et al., 2003) and Cross et al. (Cross et al., 2002) have published the results of 




different proteins (molecular concentrations) during the cell cycle of a haploid cell growing in 
asynchronous culture.  
Parameters used in the deterministic model of Chen et al. (Chen et al., 2004) do not have 
units. Matlab codes for the deterministic model are obtained from Prof. Cross‟s research group. 
Using the codes, it is possible to obtain plots for the expression of different proteins during the 
cell cycle. With slight modifications to the code, average concentrations can be found out in a 
given cell cycle. Molecular concentrations during different phases of the cell cycle can be 
estimated by equating the dimensionless average concentrations to the average molecular 
concentrations. It is proposed that a reasonable estimate of trigger values for the six different 
transitions in the model can be obtained using this approach. 
Assigning units to the parameters is discussed in Chen et al. (Chen et al., 2004) which 
might be helpful in giving the initial guess of the parameters. 
C.5. Trigger events in the VB code 
 In the deterministic version of the model, three rate constants kbub2, klte1, kmad2 are 
designed to have two different values, a higher and a lower value depending on which phase of 
the cell cycle the cell is in. When there is spindle defect, protein Bub2 will inactivate Tem1 in 
MEN pathway. Protein Lte1 will try to activate Tem1. Also, when the kinetochores are 
unattached, Mad2 dependent checkpoint signal will inactivate Cdc20.  
 Replication 
        If Relicence And (N(3) + N(4)) > Replication_Trigger Then 
            Replication = True 




            k117 = kbub2_high 
            k63 = kmad2_high 
        End If 
When the trigger for replication is satisfied, kbub2 and kmad2 are kept high to prevent the 
activation of mitotic exit network. 
 Mitosis 
        If Replication And N(3) > Mitosis_Trigger Then 
        Mitosis = True 
        Replication = False 
             k117 = kbub2_low 'decreased kbub2 
             k63 = kmad2_low  'decreased kmad2 
             k118 = klte1_high 'increased klte1 
        End If 
         When the trigger for mitosis is satisfied, kbub2 and kmad2 are kept low and klte1 is kept high 
to activate the mitosis exit network. 
 Division 
If esp1 And N(3) < Division_Triger Then 
        Division = True 
        esp1 = False 
        k118 = klte1_low ' klte1 is decreased 





APPENDIX D. TEN COMPONENT MODEL  
D.1. Description of the model 
Based on the learning from building small model of four cell cycle components, using 
stochastic formulation, the next step is to extend the understanding to build models that include 
more details and components of the cell cycle reaction network. In that direction, the stochastic 
formulation is extended to a cell cycle model containing ten components with many interactions 
among them. It is developed earlier by Hjortso (unpublished work) based on a deterministic 
model of Tyson and Novak (Tyson, 2000) and is presented here along with the modifications on 
the original stochastic model. 
A schematic of the cell cycle reaction network which is redrawn based on the model of 
Tyson and Novak (Tyson, 2000) is shown in Fig. D1. 
Various features of the cell cycle model are described as followed. Early in the G1 phase, 
the S-G2-M cyclin, CycB is low because it is rapidly degraded in the presence of active Cdh1. 
CycB is required to initiate DNA replication. Cdh1 is abundant in the early G1 phase. Cyclin-
dependent kinase inhibitor (CKI), which is also abundant in the early G1 phase keeps small 
amount of active CycB inactive. As cell mass increases, it results in an increased rate of 
formation of starter kinase (SK) transcription factor, TF. This in turn results in an increase of 
starter kinase, SK. The starter kinase causes the CKI to be phosphorylated and degraded driving 
the equilibrium between CKI, CycB and the Trimer (which is actually a dimer of Cdk/CycB and 
CKI) towards free CycB. Free CycB phosphorylates CKI and inactivates Cdh1 thus further 
increasing the CycB concentration and activates degradation of TF causing the concentration of 





Figure D1: Reaction network of budding cell cycle model. Active compounds are shown as 
circles or large pie pieces, inactive compounds as start and degraded compounds as small pieces. 
Reactions are shown by solid arrows, activation by broken arrows. (Hjortso, unpublished work) 
protein that activates degradation reaction of CycB and also activates Cdh1 from its inactive state 
thus driving the cell towards division. Finally, CycB causes phosphorylation of intermediary 
enzyme, IE, leading to the formation of IEP (P for phosphorylation) which activates Cdc20. As 
CycB drops below a threshold value, the cell divides and will return to the initial state with low 
CycB and high Cdh1, required for starting another cell division cycle.  
The model is formulated in the same way as the four component model presented earlier 
using stochastic kinetics approach. Various variables in the model are listed in the Table 1. The 
variables are the number of molecules of the different molecular species of the reaction network 





Table D1: List of variables in the model. Intermediary enzyme, IE is not used in the model 
explicitly 
Postion    
symbol  
            Species  
1 SK Starter kinase. Dimer of Cdk, called Cln2 in budding yeast, Cig2 in fission 
yeast and Cyclin D in vertebrates.  
2 TF Transcription factor for SK 
3 CKI Cyclin-dependent kinase inhibitor. Binds to Cycb to form Trimer. A quasi 
steady state equilibrium is assumed between this compound, CycB and 
Trimer. 
4 CycB S-G2-M phase cyclin. Binds to CKI to form Trimer. A quasi steady state 
equilibrium is assumed between this compound, CKI and trimer. 
5 Cdh1 The active or unphosporylated form of Cdh1 
6 Cdc20I Inactive form of Cdc20 
7 Cdc20A active form of Cdc20 
8 IEP Active form of intermediary enzyme 
9 Trimer Compound formed when CKI binds to CycB (which more accurately is a 
dimer of CyclinB and Cdk. Thus the ame trimer). A quasi steady state 
equilibrium is assumed between CKI, CycB and trimer. 
10 m Cell mass 
The cell cycle network is converted into a set of biochemical reactions associated with 
propensities which is shown in Table D2. 
Table D2: List of reactions in the 10 component model 
Reaction 
Number 
Description  Stoichiometry Propensity, Cn hn 
1 Constant rate of 
formation of CycB: 
         1 
2 Degradation of 
CycB. Three first 
order mechanisms: 
Unactivated, 
activated by cdh1 
and activated by 
Cdc20A 
        
    
           
                   
3 Formation and 
activation of Cdh1 
                                           
                   
  
1 
4 Inactivation, i.e. 
phosphorylation of 
Cdh1 
        
           
      
         
 




5 Formation and 
inactivation of 
Cdc20 
          
    
  
          
  
            
 
1 
6 Degradation of 
inactivation of 
Cdc20 
                    
7 Formation of active 
Cdc20 from 
inactive Cdc20 
      
        
       
           
 
         
8 Formation of active 
Cdc20 from 
inactive Cdc20 
from active Cdc20 
      
        
       
           
 
         
9 Formation of active 
IEP 
                               1 
10 Inactivation of IEP                
11 Formation of CKI          1 
12 Degradation of CKI 
through three first 
order mechanism 
                    
           [     
13 Formation of SK        
     
       1 
14 Degradation of SK         [SK] 
15 Formation of TF                                    
                
  
1 
16 Degradation of TF        
     
         
        
 
     
17 Degradation of 
active Cdc20 
                     
CycB, CKI and Trimer are assumed to be in equilibrium and this is incorporated by the 
quasi-steady state assumption which is handled as follows. Suppose that at t0, a reaction occurs 
that changes the number of molecules of CKI and CycB. After this reaction has occurred, the 




       ,                  
which obviously do not satisfy the equilibrium assumption. The molecular numbers after 
equilibrium has been attained are determined from the equilibrium equation and two 
stoichiometric balances 
                         
                                    
                                      
which have the solution 
        
                        
    
  
      =                       
         =                          
where  
                             
                 
                
The solution for the number of molecular species obtained from the above relation is not 
an integer. One approximation included is rounding off the solution to the nearest integer. This is 
obviously incorrect since the species involved in the quasi-steady state equilibrium must satisfy 
some probability distribution according to the chemical master equation. As a first step, model is 
simulated using this approximation. 
The parameter values used in the simulation are shown in Table D3. The simulation of 
the cell cycle model using Gillespie‟s algorithm resulted in cell cycle oscillations and one such 
result showing the time course trajectories of different state variables including the cell mass is 




Table D3: Parameter values and Trigger values used in the simulations 
Parameter and Trigger Values for the 10 component 
model 
k1 250  k15_11 5 
k2_1 0.1  k16_1 0.1 
k2_11 10  k16_11 1000 
k2_111 0.1  k17 0.1 
k3_1 0.1  Keq 0.7 
k3_11 100  
  k4_1 80  J3 10 
k4_11 20  J4 10 
k5_1 0.1  J5 500000 
k5_11 0.1  J7 100 
k6 0.1  J8 100 
k7 100  J15 100 
k8 500  J16 1 
k9 100  n 5 
k10 100  
  k11 300  Trigger Values 
k12_1 0.1  Start_Trigger 30 
k12_11 20  Division_Trigger 25 
k12_111 0.1  m_death 5 
k13_1 5  
  k13_11 150  nu 1 
k14 500  min_mass 0.2 
k15_1 10000  





Figure D2: Cell cycle oscillations from the 10 component model using quasi-steady state 
approximation 
D.2. Insilico evolution of 10 component model 
The insilico evolution simulations are run for two cases for the 10 component model with the 
quasi-steady state assumption described earlier.  
 Binary fission, with mother and daughter getting same mass at the time of division 
 A more refined approach where mother attains a mass close to critical cell mass and 
daughter gets the remaining. Start event will not occur until, the cell mass reaches a value 
equal to the critical cell mass 












(Figure D3 continued) 
 
General observations from the simulations are 
 There is no convergence in the cell mass 
 The average number of trimer molecules is continuously increasing with each iteration 
 Execution times have increased drastically with the number of iterations 
 Some of the parameters have approached values close to zero and some have moved  
towards very high values 
 Starter Kinase (SK) molecules kept on increasing as the number of iterations in the 
insilico evolutions has increased. 
The rate parameters corresponding to the formation, degradation of TF for the SK and 
also, the formation of SK reaction have attained very high values (Reactions 15, 16, 13 
respectively). This resulted in very high values for the number of starter kinase (SK) molecules 





The insilico evolution results did not give any convergence values for cell mass. The only 
change observed is the increase in the parameters corresponding to the formation and 
degradation of SK, TF. 
The results of the cell cycle model are analyzed and it is observed that the number of 
trimer molecules in a cell have gradually increased as the number of cell divisions increased for 
the same set of parameters and also cell mass has increased. 
It is suspected that the problem might be in the quasi-steady state assumption. 
Hence, the handling of QSSA in the model is reconsidered. 
D.3. Original Stochastic Algorithm and Simulation of the 10 Component Model 
The equilibrium reaction is re-written as two separate reactions and the resulting reaction 
set is simulated using stochastic simulation algorithm of Gillespie with high propensity values 
for the two equilibrium reactions. Hence, the two reactions corresponding to the equilibrium 
occur very fast and thus have the chance of being fired frequently than the other reactions which 
are slow reactions. However, the dynamics of the system can be described only if large numbers 
of slow reactions have occurred. 
As expected, the computational time is wasted by simulating the fast reactions most 
frequently and the simulations took long time to obtain the time course of different cell cycle 
proteins. The two additional reactions along with their propensities are shown in the Table D4. 








Table D4: Two reactions added to the stochastic chemical kinetic model, by avoiding the quasi-
steady state assumption  
Reaction 
Number 
Description Stoichiometry Propensity, Cn hn 
18 Formation of 
Trimer 
                  k18             
19 Dissociation of 
Trimer 
                  
 
k19          
 
 
Figure D4: the simulation results for the 19 reactions. The execution time is 80832 sec for three 
completed cell cycles. (10 time units in the model) 
D.4. Slow Scale Stochastic Simulation 
It is thought that the QSSA assumption needs to be reconsidered. Cao et al. (2005) 
proposed a slow-scale stochastic simulation approach to handle the reactions involving slow and 
fast reactions occurring on widely different time scales. The description of the approach and its 
application to the 10 component model is presented here. 
 The reactions are classified into slow and fast reactions depending on the reaction 




reactions are fast reactions and the rest are slow reactions. Reacting species are also classified as 
slow and fast. Any species whose population gets changed by the occurrence of fast reaction is 
defined as fast species and the species that does not get changed by the fast reaction is defined as 
slow species. 
 The fast and slow reaction propensity functions depend in general on both the fast and 
slow species which are represented as: 
  
        
                  
  
        
                  
  is the generic representation of the state of the system which contains slow (  ) variables and 
fast variables (  ).  
   is the number of fast reactions and    is the number of slow reactions. 
According to slow-scale SSA, if two conditions are satisfied, the state of the system evolution 
can be described in terms of the occurrence of slow reactions alone. Those are, 
 The time scales of fast reactions are very small compared to the time scales of slow 
reactions. Then, a large number of fast reactions occur between two successive slow 
reactions. 
 The fast variables reach a steady state between the occurrence of two slow reactions. 
When a slow reaction occurs, state of the system is updated and this change in the state of 
the system affects the propensities of fast reactions. As a result, many fast reactions occur 




If the above conditions are satisfied, slow reactions and fast reactions can be considered 
as two discreet markov processes occurring on different time scales. 
 Fast reactions follow a discreet markov process with slow reactions turned off. The stable 
state of the system after a series of fast reactions is obtained by solving the steady state CME. 
Steady state solutions of CME are available for simple reactions as described in McQuarre 
(McQuarre, 1967). 
 The slow reactions also follow a discreet markov process. The propensities required for 
simulating the slow reactions are calculated based on the weighted average of the propensities of 
the steady state distribution of states obtained from the solution of CME for fast reactions. 
D.5. Application of the Slow-Scale SSA to the Ten Component Model 
The steps of the algorithm are explained by using the example of the 10 component model. 
1. Initialize the state of the system as    
 
   
   in terms of fast and slow variables. 
For the 10 component model, 
                     
                                  
2. Calculate the propensity function   
           for each slow reaction (  ).   
           is 
the average of the regular propensity functions of    over the distribution of the fast 
variables obtained from the steady state CME of the fast reactions. 
  
                 
 
   
  
 
         
    
 
     
   is the steady state probability distribution of the fast variables, when the system is initially in 




For the present equilibrium reaction, 
         
 
          
   
  
  
, is the equilibrium constant of the dimerization reaction.       are the equivalent 
forward and reverse rate constants for the dimerization reactions. 
The probability distribution is derived by solving the steady state master equation. 
    
 
    
      
        
      
        
   
      are the initial state of the fast variables,                 respectively, from which 
final steady state distribution of the state is evaluated from the steady state CME of fast 
reactions.   is the equilibrium constant of the dimerization reaction. 
   is the probability of finding „ ‟ number of molecules of CycB when the state of the system is 
evolving from the initial state (        ) according to the CME of the equilibrium dimerization 
reaction. 




    
      
        
      




  is the maximum number of molecules of CycB that can be observed for the given initial state. 
       
The other fast variables are calculated from the stoichiometric relations, 
[                
                       
3. The next slow reaction (µ) and the time ( ) at which it occurs is calculated from the 




Calculate,   
              
          
  
   
 
Generate uniformly distributed random numbers in [0,1], r1 and r2 
Select    
 
  
           
           
Select µ as an integer satisfying,   
          
   
   
     
              
          
 
   
 
4. Update the system according to the occurrence of the slow reaction, µ. 
5. The new state after the update,         changes the propensities of the fast reactions and 
the system attains a new set of stationary values of fast variables. The new state is 
selected randomly following the steady state distribution of fast variables. 
                     
Then,           
   
6. The procedure is repeated until the end time. 
In the above procedure, selecting the state of the fast variable according to the probability 
distribution given by      
 
          is a difficult task. 
A simplification is suggested by Cao et al. (2005) in their slow-scale SSA work. If the 
distribution is unimodal, it can be represented by an equivalent normal distribution with the 
mean and variance calculated from the discreet markov process representation of the fast 
reactions.  
The mean of the state,   is calculated as the root of the equation,  
                      
Where,         is the probability that the state will be     ) in the time interval 




For the present system,  
                                  
                            
From the above relationships, the mean value of the final state in fast variables, starting 
from the initial state          is given by,  
        
                            
              
   
  
Variance of the equivalent normal distribution is given by,  
    
     
      
 
For the present case,  
    
                     
                    
 
These expressions of mean and variance provide an approximate way to choose the stable 
state of fast variables between two successive slow reactions, without using the cumbersome 
probability distribution mentioned earlier. 
D.5.1. Calculation of the Average Reaction Propensities for the Slow Reactions 
Calculation of the weighted average of the reaction propensity function given by  
  
                 
 
   
  
 
         
    
 
     
Simplifications can be made for trivial reactions such as simple unimolecular, bimolecular 
reactions.  
When   
             
 
, then   
               




When   




, then   
               
 
   
   
By knowing the first and second moments of the fast variables above expressions can be 
evaluated. 
The similar adjustments are made to the propensity functions of the ten component 
model, using the mean value of CycB,       . For example, propensity function for the 9th 
reaction in the reaction network is calculated as: 
                             
Whenever, such adjustments are not possible, a deterministic approximation is made. For 
example, propensity function for 5
th
 reaction is calculated as: 
     
    
  
          
  
            
 
It is not quantified, how much such adjustments can induce errors in the model predictions. It is 
taken as an initial approximation towards implementing the multi-scale simulation approach for 
the cell cycle model. 






Figure D5: Simulation results for the slow scale stochastic simulation approach. The execution 
time is 214 sec for three completed cell cycles. (10 time units in the model). The accuracy of the 





APPENDIX E. REVIEW OF MATHEMATICAL MODELS IN CHEMOTHERAPY 
There are many models described in the literature and they have different objectives and 
goals in the context of chemotherapy studies. These models vary from simple tumor growth 
models that focus on finding out the administration strategies without including details like 
pharmacokinetics, drug resistance to complex models that follow an integrated approach with 
aiming for tailoring the treatments to individuals and for in silico screening of potential drugs. 
Norton and Simon (1986) developed a mathematical model assuming non-exponential 
growth for tumors without considering drug resistance. They propose that the rate of regression 
of tumor is proportional to the growth fraction of an unperturbed tumor of the same size and 
conclude that the dose of the drug should be intensified as the size of the tumor decreases. This 
concept of late intensification is well known as the Norton and Simon Hypothesis.  Jansson 
(1975) (Jansson, 1975) developed cell cycle phase specific model that includes cell 
differentiation and heterogeneity with capability to obtain growth dynamics of cancer cells, 
normal cells in parallel with a separate use of cell cycle kinetic parameters. Through the model, 
the researcher Identifies treatment protocols that show improvement for cancer reduction and 
toxicity control. Webb (1990) studies the resonance phenomenon discovered by Dibrov (Dibrov 
et al., 1985) considered to be significant in periodic administration of chemotherapic drugs 
according to which toxicity to normal cells can be minimized by adjusting the treatment period 
close to the mean cell cycle length of normal cells. An age and size structured population balance 
model accounting for cell cycle variability is used for cancer cells and normal cells with different 
parameters. Drug action is instantaneous and drug PD is introduced by including periodic cell 
loss function that is „on-off‟ destruction of cells. Augur et al. (1988) (Agur et al., 1988) develop 




(Sundareshan and  Fundakowski, 1984) for intrinsic population growth and dividing cell cycle 
into drug resistant and sensitive phases. The model based on different parameters for normal and 
cancer cells evaluates periodic treatment protocols based on elimination times of both types of 
cells under treatment. 
Many models are described by applying optimal control theory to obtain best drug 
administration profiles during the treatment period. These models focus on different objectives 
such as minimizing the tumor size, maximizing the bone marrow population under treatment 
constraints generally using compartmental models. A review of cell cycle non-specific models 
using optimal control is presented by Swan (1990) and Swierniak et al. (Swierniak et al., 2003) 
presents cell cycle specific models. Ledzewicz & Schattler (2007) derive optimal drug schedules 
based on a cell cycle non-specific model to minimize the bone marrow depletion using simple 
PD and PK. Ledzewicz & Schattler (2002) present a cell cycle specific model for minimizing 
cancer cells at the end of the treatment. Fister and Panetta (2000) (Fister and  Panetta, 2000) 
apply optimal control theory to maximize both bone marrow and the amount of drug dose to kill 
cancer cells using cell cycle specific three compartmental model. In the model by Dua et al. 
(2008) (Dua et al., 2008), growth dynamics of both normal cells and cancer cells are described 
using different growth equations and optimal control problem is formulated to minimize the total 
tumor size after some time while restricting the toxicity to the normal cells. Two different 
models are solved for cell cycle specific and cell cycle non-specific treatments by coupling to 
PK/PD models. Ledzewicz & Schattler (2005) proposed a cycle non-specific model using a two 
compartmental model to demonstrate that addition of PK/PD models does not change the optimal 
solution of drug doses and scheduling. Dibrov (1985) discovered the phenomenon of resonance 




their age structured model for heterogeneous cell population used for both normal and cancer 
cells with different model parameters. They suggest that the drug administration should be 
periodic rather than continuous and also the period of drug administration should be small and 
more frequent. They determine the optimum period is close to the value of the cell cycle length 
when large variations exist between the normal and cancer cells. 
Models are developed with the aim to determine the drug schedules to minimize the 
evolving drug resistance during the treatment. (Goldie and  Coldman, 1983) presented their point 
mutational stochastic model for drug resistance for non cell cycle specific drugs by assuming 
instantaneous action of drug. Their model considers two non-cross resistant identical drugs 
which can be extended for multiple drugs. Later, Day (1986) relax the symmetry assumption for 
drugs and suggest administration strategies based on a multi type branching process model (Day, 
1986). These models do not consider cell cycle effects and only study chemotherapy scheduling 
in the context of drug resistance. Gaffney (2004) combine cell cycle effects with drug resistance 
using their age structured population balance model and suggest schedules to reduce the 
probability of development of drug resistance. A branching random walk model is developed by 
Kimmel and Swiernaik (2006) (Kimmel and  Swierniak, 2006) in which they apply optimal 
control theory for designing chemotherapic scheduling by including cell cycle effects and drug 
resistance through gene amplification mechanism. 
More complex models include features like stochasticity, quiescence, drug 
pharmacokinetics, pharamacodynamics, drug resistance, spatial variations in a detailed 
formulation, in some cases based on experimentally derived parameters. Sherer et al. (2006) 
(Sherer et al., 2006) examined the resonance effect in chemotherapy using a multi-staged age 




death rates. Dividing cells into six different phases, their model is used to study the influence of 
in vivo effects such as quiescence, drug metabolism, drug properties, and transport 
considerations on the resonance chemotherapy.  Sherer et al. (2007) (Sherer et al., 2007), 
through an age structured binary cell division population balance model, present probabilistic 
interpretations for obtaining treatment durations that result in complete cancer cure. The model 
considers variable response of patients to treatment and presence of dormant population while 
not considering the cell cycle effects, toxicity to normal cells and drug pharmacokinetics. 
Another model (Coldman and  Murray, 2000) applies optimal control techniques to consider 
multiple determinant of chemotherapy – toxicity, drug resistance, tumor control, which are 
separately handled separately by many other optimal control models. A birth and death type of 
stochastic model is used neglecting PK/PD effects. Model by Panetta et al. (2008) (Panetta et al., 
2008) combines PK/PD models with models for cancer growth and neutrophil production in the 
bone marrow to demonstrate its usefulness in the clinical practice. Based on the experimentally 
derived parameters, they aim to identify the schedules and exposure times for improved tumor 
response with minimized toxicities. In another study (Stamatakos et al., 2006), a spatiotemporal 
Monte Carlo simulation model of tumor response to chemotherapy is developed based on three 
dimensional structural and functional information from tumors of individual patients. Toxicity 
and drug resistances are neglected. 
An integrative approach that combines different modules at different scales for 
chemotherapy studies will be useful for predicting invivo tumor growth and response to 
chemotherapy and thus helpful in achieving the much desired goals of cancer research 
community – for screening potential drugs in silico and for tailoring treatments to individual 




integrates tumor growth in spatial domain, tumor induced angiogenesis, drug resistance, PD and 
PK that is suitable for application of multiple drugs. Venkatasubramanian (2008) developed an 
integrated model where cell cycle transitions are described based on energy metabolism and 
spatial heterogeneity of tumor is considered. Neglecting toxicity, drug resistance their integrated 
model studies the effect of PK, PD on treatment efficacy. (Kolokotroni, 2008)  describe a multi-
scale spatiotemporal, patient specific model that integrates PK, PD and cell cycle kinetics by 
considering different types of cells such as stem cells, cells with limited mitotic capability, 
differentiated cells, necrotic cells, dead cells. Their model based on the data from individual 
patients is aimed at translating the integrated model into clinical practice for optimizing cancer 
treatment in the patient individualized context.  
Another model that has integrated many modules of integrated chemotherapy model 
framework is OncoTCap (Oncology Thinking Cap) developed by Day and colleagues (Day R, 
1998; Gardner and  Fernandes, 2003). This simulation tool,  developed based on the multi-type 
branching process model by (Day, 1986), is capable of describing phenomena such as 
heterogeneity in cell kinetics, random mutations, cell death due to chemotherapic treatment, drug 
resistance, quiescence, stem-cell differentiation, metastasis, spatial heterogeneity and gene 
amplification, however with the high dependence on computational power. The model derives a 
cumulative probability generating function of different types of cells which can be used to find 
out the probability of cure of a given treatment, effect of different treatment schedules on the 
heterogeneous cell population.  However, drug action is assumed to be instantaneous and cell 
cycle specificity, drug pharmacokinetics are neglected. OncoTCap simulation tool was used for 
educating medical students about clinical trials (Day et al., 2004). In another study, Gardner 




exponential and gompertzian growth, drug resistance, multi drug testing capability, PK,PD, intra-
tumor heterogeneity, apoptosis, quiescence based on experimentally derived parameters. The 
same model can be used for tumor cells and for different types of normal cells accounting for 
toxicities, by using different parameters. The model is demonstrated to tailor the treatments to 
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